1	Unveiling Shared Genetic Links between Blood Cell Traits and Cardiovascular
2	Diseases
3	Luke Kong ^{1#} , Kaixin Yao ^{2#} , LeiLei Zheng ^{3#} , Yuhui Zhao ⁴ , Miaoran Chen ² , Ziyi Han ⁵ ,
4	Qian Wang ⁶ , Qifan Feng ⁴ , Yongqiang Lv ^{7*} , Biyun Zhang ^{8**} , Feng Li ^{8***}
5	¹ Department of Medical Laboratory, Jincheng People's Hospital, Jincheng, China.
6	² Department of Nephrology, Second Hospital of Shanxi Medical University, Taiyuan,
7	China.
8	³ Department of Otolaryngology-Head and Neck Surgery, Second Hospital Shanxi
9	Medical University, Taiyuan, China.
10	⁴ Department of Rheumatology, Second Hospital of Shanxi Medical University,
11	Taiyuan, Shanxi, China.
12	⁵ Department of Medical Oncology, First Hospital of Shanxi Medical University,
13	Taiyuan, China.
14	⁶ Department of Nephrology, Shanxi Provincial People's Hospital, The Fifth Clinical
15	Medical College of Shanxi Medical University, Taiyuan, Shanxi, China.
16	⁷ Department of Quality Control, Shanxi Cancer Hospital/Shanxi Hospital Affiliated
17	to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated
18	to Shanxi Medical University, Taiyuan, China.
19	⁸ Central laboratory, Shanxi Cancer Hospital/Shanxi Hospital Affiliated to Cancer
20	Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi
21	Medical University, Taiyuan, China.
22	
23	*Correspondence to:
24	Feng Li MD, PhD
25	Professor
26	Central laboratory, Shanxi Cancer Hospital/Shanxi Hospital Affiliated to Cancer
27	Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi
28	Medical University, Taiyuan, 030013, China.
29	Tel: +86 15935369999
30	E-mail: lifenglover@sina.com

31

- 32 Biyun Zhang,
- 33 Professor
- 34 Central laboratory, Shanxi Cancer Hospital/Shanxi Hospital Affiliated to Cancer
- 35 Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi
- 36 Medical University, Taiyuan, 030013, China.
- 37 Tel: 86-18406593082
- 38 E-mail: z18406593082@163.com
- 39
- 40 Yongqiang Lv MD, PhD
- 41 Professor
- 42 Department of Quality Control, Shanxi Cancer Hospital/Shanxi Hospital Affiliated to
- 43 Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to
- 44 Shanxi Medical University, Taiyuan, China.
- 45 E-mail: lyq820529@163.com

46 Abstract

47	Previous studies have linked blood cell traits (BCTs) to cardiovascular diseases
48	(CVDs) risks, but the common genetic mechanisms underlying heritable phenotypes
49	remain unclear. Our study used multiple analytical approaches including single
50	nucleotide polymorphisms, genes, pathways, and protein targets to reveal common
51	genetic elements. We confirmed both genome-wide and local genetic associations
52	between BCTs and CVDs, identifying key pleiotropic loci and genes contributing to
53	these links. Specifically, ALDH2, MAPKAPK5, and ACAD10, all located at 12q24.1,
54	are associated with leukocyte-CVD traits. TNFSF12 at 17p13.1 and ABO at 9q34.2
55	correlate with platelet-CVD traits, while ZNF664 and CCDC92, also at 12q24.1, are
56	linked to erythrocyte-CVD traits. Our findings also highlight multiple key
57	trait-specific pathways mediating these phenotypic associations and potential
58	therapeutic targets that may inform future clinical interventions. These insights
59	significantly advance our understanding of the genetic interplay between BCTs and
60	CVDs, underscoring the importance of focusing on BCTs to prevent cardiovascular
61	conditions.
62	
63	Keywords
64	Blood cell traits, Cardiovascular disease, Shared genetic architectures, Genetic
65	correlation, Genome-wide association studies, Pleiotropic analysis.
66	
67	Highlights
68	• There were wide genetic correlation and overlap between BCT and CVD.
69	• Key pleiotropic loci and genes for three BCT-CVD trait pairs were identified.
70	• Key signature-specific pathways mediating the BCTs-CVDs association were
71	identified.
72	• Potential therapeutic targets for BCTs-CVDs were identified.
73	
74	eTOC blurb

Kong et al. report extensive genetic correlations and genetic overlaps between blood
cell traits (BCTs) and cardiovascular diseases (CVDs), revealing key pleiotropic loci
and genes contributing to these associations, as well as multiple trait-specific
pathways mediating these phenotypic associations. Potential therapeutic targets to
inform future clinical interventions were also identified, laying the foundation for
understanding the genetic interactions between BCTs and CVDs.

81

82 Introdution

Cardiovascular diseases (CVDs), which encompass a range of conditions affecting the 83 heart and blood vessels, are the leading cause of death and disability worldwide^{1,2}. A 84 primary contributor to CVDs, atherosclerosis, is significantly influenced by various 85 blood cell traits (BCTs)^{3,4}. For example, erythrocytes, critical in maintaining 86 physiological hemodynamics, can exacerbate arterial wall pathologies and, through 87 88 interactions with immune cells, potentially accelerate atherosclerosis due to oxidative stress⁵. Similarly, the secretory functions of leukocytes, especially lymphocytes, are 89 90 pivotal as they release proinflammatory cytokines and proteases that may lead to plaque rupture⁶. Platelets also play a key role in hemostasis and thrombosis and 91 92 enhancing the inflammatory environment, thus promoting the recruitment of inflammatory cells to lesions and releasing inflammatory mediators⁷. Extensive 93 observational research has consistently demonstrated a robust association between 94 alterations in BCTs and increased risk of CVDs. Recent studies have identified 95 96 erythrocyte count (RBC), hematocrit (HCT), mean corpuscular volume (MCV), and red cell distribution width (RDW-CV) as potential biomarkers for cardiovascular 97 98 risk.⁸. Additionally, conditions characteristic of CVDs can prompt the bone marrow to 99 release immature cells or increase other cell populations, depending on the severity. 100 Notably, the leukocyte is a cost-effective, widely used diagnostic tool in clinical practice, with insights from the Framingham Heart Study highlighting its role as an 101 indicator of elevated CVD risks⁹. More precise predictions of CVD risk come from 102 specific leukocyte subtypes, such as monocytes¹⁰, lymphocytes¹¹, and neutrophils¹², 103 rather than total leukocyte count (WBC) alone. Furthermore, studies have shown that 104

platelet metrics like platelet component distribution width (PDW), mean platelet
volume (MPV), and platelet count (PLT) are critical indicators of CVD risk¹³. These
insights underscore the importance of monitoring alterations in blood cell functions
for effective diagnosis, risk stratification, and predicting outcomes in CVDs.

109

Epidemiological studies have consistently shown that BCTs are closely associated 110 with CVDs, with this relationship likely influenced by shared genetic factors^{14,15}. 111 Genome-wide association studies (GWAS) have identified numerous genetic variants 112 common to both BCTs and CVDs, such as SH2B3 and HFE, which are associated 113 with RBC and coronary artery disease (CAD), respectively¹⁶⁻¹⁸. This suggests that 114 pleiotropy, the influence of a single genetic variant on multiple traits, may be 115 fundamental to understanding the genetic basis of these complex traits. Pleiotropy 116 manifests in two primary forms: vertical and horizontal¹⁹. Vertical pleiotropy occurs 117 when single nucleotide polymorphisms (SNPs) influence one trait, which 118 119 subsequently affects another, permitting the use of Mendelian randomization (MR) to 120 estimate causal relationships between traits. For example, Hashfield et al. 121 demonstrated a positive causal relationship between PLT and eosinophil percentage of leukocytes (EO P) with an increased risk of ischemic stroke and its subtypes²⁰. 122 Similarly, genetic predispositions towards high RBC and low monocyte count 123 (MONO) correlate with increased venous thromboembolism (VTE) risk²¹. However, 124 existing MR studies have yet to explore these trait categories fully. On the other hand, 125 126 horizontal pleiotropy occurs when a genetic variant independently affects multiple 127 phenotypes or influences intermediate processes between these phenotypes. Recent 128 advances in statistical tools for genomics have underscored the importance of 129 horizontal pleiotropy in elucidating the shared genetic basis of complex traits. For example, Yang et al. reported an extensive landscape of genetic correlations between 130 29 BCTs and 11 neurological and psychiatric diseases²². Despite these insights, 131 previous studies have yet to comprehensively explore the relationship between BCTs 132 133 and CVDs. The complex association patterns and underlying mechanisms of their 134 connection remain largely uncharted. Therefore, systematic analyses are necessary to

determine whether shared genetic architectures and molecular pathways exist between

BCTs and CVDs, potentially unveiling new insights into their biological mechanisms.

137

138 In this study, we comprehensively analyzed the latest and most extensive GWAS 139 summary data from individuals of European ancestry to uncover the shared genetic 140 architecture and mechanisms underlying 29 BCTs and six major CVDs (Table 1). Our 141 initial analyses focused on identifying the shared genetic structure between BCTs and 142 CVDs, utilizing methods to analyze genetic correlations and overlaps. Then, 143 employing MR analysis within a framework of vertical pleiotropy, we explored 144 evidence for causal relationships between BCTs and CVDs. This groundwork 145 facilitated a cross-trait analysis, pinpointing pleiotropic SNPs at the SNP level, and 146 allowed us to identify candidate pleiotropic genes through positional mapping and 147 expression quantitative trait loci (eQTL) mapping. Further investigations included an 148 enrichment analysis of biological pathways and the identification of pathogenic 149 plasma proteins, assessing their potential as therapeutic targets. This multifaceted 150 approach has illuminated complex genetic networks linking hematological markers to 151 cardiovascular health, offering insights that could pave the way for novel diagnostic 152 and therapeutic strategies.

153

154 Result

155 Genome-wide genetic correlation between BCTs and CVDs

We assessed the SNP-based heritability (h^2_{SNP}) of 29 BCTs and 6 major CVDs using 156 157 linkage disequilibrium (LD) score regression (LDSC) and performed genome-wide genetic correlation (r_g) analysis of these 174 trait pairs. Univariate LDSC analysis 158 159 showed that h_{SNP}^2 estimates for BCTs were consistently higher than those for CVDs, ranging from 5.2% to 34.9%, with the highest estimate for MPV ($h_{SNP}^2 = 34.88\%$, SE 160 = 0.036). In contrast, h^2_{SNP} estimates for CVDs were significantly lower, all below 5%, 161 with the smallest estimate for Stroke ($h^2_{SNP} = 0.60\%$, SE = 0.0005) and the highest 162 estimate for CAD ($h_{SNP}^2 = 3.25\%$, SE = 0.0019) (Supplementary Table 1). Subsequent 163 bivariate LDSC analysis found nominally significant associations for 36 (20.3%) of 164

165 174 trait pairs (P < 0.05). Of these, 26 trait pairs showed positive r_s , especially 166 between WBC and PAD, with a r_g of 0.115 (SE = 0.053). In contrast, the most 167 significant negative r_g was between mean corpuscular hemoglobin concentration (MCHC) and VTE, with a r_g of -0.101 (SE = 0.028). Using a less stringent 5% false 168 169 discovery rate (FDR) threshold, we found that three blood cell count-related traits, 170 including platelet crit (PCT), PLT, and MCHC, were associated with a lower risk of 171 VTE. Six different BCTs (neutrophil count (NEUT), WBC, high light scatter 172 reticulocyte count (HLR), high light scatter percentage of red cells (HLR_P), 173 reticulocyte count (RET), and reticulocyte fraction of red cells (RET_P)) were 174 significantly associated with an increased risk of CAD. In contrast, six different BCTs 175 (immature fraction of reticulocytes (IRF), mean corpuscular hemoglobin (MCH), 176 MCV, mean reticulocyte volume (MRV), mean spheric corpuscular volume (MSCV), 177 and red cell distribution width (RDW_CV) were significantly associated with an 178 increased risk of VTE. Notably, four trait pairs previously identified as having the 179 same direction of genetic correlations (including HLR-CAD, MRV-VTE, MCV-VTE, and RDW_CV-VTE) confirmed significant correlations between them^{21,23-26} (Fig. 1 180 181 and Supplementary Table 2).

182

183 Local genetic correlation between BCTs and CVDs

184 LDSC is used to estimate additive genetic effects on traits across the genome, 185 however, when genetic signals show opposite correlations in different genomic 186 regions, the cumulative genome-wide r_g can asymptotically approach zero. To address 187 this issue, we used Local Analysis of [co] Variant Annotation (LAVA) to perform 188 more detailed analyses within shorter genomic regions, specifically focusing on local 189 genetic correlations (local- r_{es}) between 29 BCTs and 6 CVDs. Applying it to 80,126 190 regions, we identified 28,887 univariate genetic signals associated with BCTs in 2,219 191 unique regions and 2,716 signals associated with CVDs in 1,472 unique regions, all with p-values less than 1×10^{-4} (Supplementary Table 3). Subsequent bivariate analysis 192 193 revealed significant local- r_{gs} (FDR < 0.05) for all trait pairs, covering 5,233 genetic 194 regions (including 898 unique regions)(Supplementary Fig.1 and Supplementary

195 Table 4). Interestingly, there is mixed local genetic effects on trait pairs where 196 genome-wide r_g is not significant. For example, between MSCV and CAD, 41.4% of 197 the partitions showed positive associations, 59.6% showed negative associations, 198 suggesting that genome-wide r_g may underestimate the polygenic overlap of these 199 trait pairs. Notably, LD block 1841 on chromosome 12 was associated with more than 200 half of the trait pairs, followed by LD block 1479 on chromosome 9 and LD block 201 1480 on chromosome 12, which showed correlations with 68 and 47 trait pairs, 202 respectively. Then, Hypothesis Prioritisation for multi-trait Colocalization 203 (HyPrColoc) further identified the common causal variants among them and indicated 204 a high association frequency for pleiotropic SNPs in the 12q24.12 region. Notably, 205 rs3184504 (mapped to the SH2B3 gene) showed strong evidence of colocalization 206 between 19 BCTs and 2 CVDs (CAD and VTE), with a posterior probability (PP) >207 0.7. In addition, rs4378452 (mapped to the CUX2 gene) was identified as a potential 208 common causal variable between 22 BCTs and CAD.

209

210 Extensive genetic overlap between BCTs and CVDs

211 Consider that r_g can not characterize detailed association patterns at individual loci, 212 and nonsignificant estimates do not necessarily indicate the absence of a common 213 genetic background. Therefore, we further applied genetic analysis combining 214 pleiotropy and annotation (GPA) approach to explore the overlapping genetic variants 215 of 29 BCTs and 6 CVDs, enhancing the understanding of the common genetic 216 landscape of BCTs and CVDs. GPA analysis revealed that all BCTs-CVDs trait pairs 217 exhibited varying degrees of genetic overlap at a 5% FDR threshold, regardless of 218 whether the genome-wide r_g was significant (Supplementary Fig.2 and Supplementary 219 Table 5). Notably, reticulocyte count (RET) and CAD showed a relatively high 220 proportion of shared SNPs (proportion of association ratio (PAR) = 25.4%), consistent 221 with their significant genetic correlation ($r_g = 0.107$). Among the 138 BCTs-CVDs pairs with non-significant genome-wide r_g , the overlap between CAD and MSCV was 222 223 particularly pronounced, with a shared genetic overlap of 24.1%. As for IRF-VTE, as a significant genome-wide r_g trait pair, the proportion of pleiotropic SNPs is only 224

19.0%, which is lower than MSCV-CAD. In summary, we confirmed the presence of shared genetic structure in all trait pairs using LAVA and GPA approaches. Although some trait pairs did not show evidence of genome-wide r_g , possibly due to confounding effects, our analyses highlight potential genetic links that contribute to the complex relationship between BCTs and CVDs.

230

231 Mendelian Randomization between BCTs and CVDs

232 To investigate vertical pleiotropy between 29 BCTs and 6 CVDs, we employed Latent 233 Heritable Confounder Mendelian Randomization (LHC-MR) to evaluate causal relationships. The forward analysis identified seven causal relationships that achieved 234 235 Bonferroni-corrected significance, including positive associations for RDW-VTE, 236 basophil percentage of leukocytes (BASO_P)-AF, and BASO_P-CAD. For example, 237 an elevated RDW_CV was associated with an increased risk of VTE (OR = 1.08), 238 whereas a higher IRF was linked to a reduced risk of CAD (OR = 0.91), indicating 239 negative causal relationships. The reverse analysis uncovered twelve positive causal 240 relationships, such as AF, with an increased MCV (OR = 1.52). In contrast, four pairs 241 showed negative causal relationships, notably VTE associated with a decreased 242 RDW_CV (OR = 0.71). Remarkably, only the pair PCT-CAD exhibited a bidirectional 243 causal relationship. These findings suggest that although some trait pairs demonstrate 244 distinct causal connections, most associations between BCTs and CVDs are not driven by underlying causal factors(Fig. 2, Supplementary Fig. 3, Supplementary Table 6 and 245 246 Supplementary Table 7).

247

248 Shared Loci between BCTs and CVDs

Although the above three approaches have enhanced our understanding of the general pleiotropy between BCTs and CVDs, they still need to elaborate on the association patterns of individual loci and clarify their shared genetic architecture from the perspective of vertical and horizontal pleiotropy. To fill this gap, we employed the Pleiotropic Analysis under the Composite Null Hypothesis (PLACO) to identify horizontal pleiotropic SNPs mediating the association between BCTs and CVDs. A

total of 571,782 SNPs ($P < 5 \times 10^{-8}$) were identified as significant pleiotropic variants 255 256 across all BCT-CVD pairs (Fig. 3 and Supplementary Table 8). Notably, the PLT-CAD 257 pair exhibited the most pleiotropic associations with 176 pleiotropic SNPs, followed 258 closely by RBC-CAD (173 pleiotropic SNPs) and MSCV-CAD (168 pleiotropic 259 SNPs), consistent with the significant genetic overlap between these trait pairs. 260 Subsequently, 571,782 pleiotropic SNPs were clustered into 13,697 genomic loci in 261 580 unique chromosomal regions using functional mapping and annotation (FUMA). 262 Specifically, 11,810 loci were associated with BCTs, 3,904 with CVDs, and 2,622 263 were shared between BCTs and CVDs. Notably, 12 chromosomal regions were shared 264 by at least half of the trait pairs, including regions 9q34.2, 12q24.12, 12q24.31, and 265 19p13.2. We also observed mixed directions of allelic associations, with 6,721 top 266 SNPs (49.1%) consistently associated with specific traits, indicating that these variants can either simultaneously reduce (3,185 SNPs) or increase (3,536 SNPs) the 267 268 number/percentage of BCTs and CVDs risks. In contrast, the remaining 50.9% of the 269 top SNPs showed opposite associations with specific traits, suggesting the presence of 270 different biological mechanisms.

271

272 For functional annotation, we utilized ANNOVAR and discovered that 8,201 (59.9%) of the variants were intronic, 3,749 (27.4%) were intergenic, and 523 (3.8%) were 273 exonic. Among these, the index SNP rs1613662 at the 19q13.42 locus ($P_{PLACO} = 9.26$ 274 $\times 10^{-10}$ for basophil count BASO-VTE and PLT-VTE) was related to an adipose 275 visceral omentum eQTL ($P_{Adipose_Visceral_Omentum} = 1.49 \times 10^{-5}$), encoding the collagen 276 receptor GPVI/FcRy, primarily involving GP6 variants (Supplementary Table 10). 277 278 This receptor interaction with subendothelial collagen exposed after vessel wall injury can promote platelet activation and aggregation, thus affecting the risk of $VTE^{2/2}$. 279 280 Additionally, combined annotation-dependent depletion (CADD) scores revealed that 1,031 SNPs had scores greater than 12.37, with rs116843064 in the 19p13.2 region 281 282 having the highest CADD score of 33. A total of 484 top SNPs were found to

283 potentially affect transcription factor binding and correlate with gene target 284 expression. Among these, six SNPs, including rs4987082, rs12440045, rs6511703, 285 rs1214761, rs9810512, and rs6882088, had the highest credibility for regulatory 286 functions (RegulomeDB score: 1a). We further performed colocalization analysis on 287 13,697 potential pleiotropic loci, of which 1,709 (12.5%) showed strong 288 colocalization evidence (PPH4 > 0.7). Notably, the 12q24.31 locus affected 46 trait 289 pairs, with PP.H4 values ranging from 0.740 to 0.995, demonstrating significant 290 pleiotropy.

291

292 Candidate pleiotropic genes by position mapping

293 We further integrated these pleiotropic SNPs to the gene level using multi-marker analysis of genomic annotation (MAGMA) and identified 10,106 significant 294 pleiotropic genes (1,973 unique genes) ($P < 1.63 \times 10^{-8}$) (Fig. 3, Supplementary Table 295 296 12). Notably, 1,453 (73.6%) of these genes were widely shared between two or more 297 trait pairs. For example, ATXN2, ACAD10, ALDH2, CUX2, BRAP, SH2B3, and 298 MAPKAPK5 were identified as significant pleiotropic genes in 69, 67, 64, 61, 58, 58 299 and 56 trait pairs, respectively. These genes are located in the 12q24.11-12q24.13 300 region, known for its pleiotropic effects on PCT and various cardiometabolic traits, 301 including fasting glucose, blood pressure, and obesity-related traits (body mass index 302 (BMI) and waist-to-hip ratio (WHR)). Depleting the cytoplasmic protein encoded by 303 ATXN2 has resulted in defective platelet aggregation and dysregulation of hemostatic processes²⁸. Additionally, polymorphisms in ATXN2 significantly affect the 304 kynurenine level in erythrocytes²⁹ and are critical loci for systolic (SBP) and diastolic 305 blood pressure (DBP), as well as mean arterial pressure (MAP)³⁰. Consequently, 306 307 ATXN2 plays a pivotal role in the onset of various CVD events by regulating blood 308 pressure. To ensure the robustness of our findings, SNPs were positionally remapped 309 using the SNP2GENE function of FUMA, which verified 88.5% of the genes 310 identified by MAGMA (Supplementary Table 10). Further comparisons of the 311 PLACO-based MAGMA results with single trait GWAS data for BCTs and CVDs

revealed 855 (8.5%) novel genes for BCTs, 4,938 (48.9%) novel genes for CVDs, and

313 229 genes that overlapped between BCTs and CVDs (Supplementary Table 12).

314

315 Candidate tissue-specific pleiotropic genes by eQTL mapping

316 To elucidate how the above SNPs affect gene expression in a tissue-specific manner, we first used LDSC-specific expression (LDSC-SEG) to determine the tissue 317 318 association corresponding to each trait. We found that BCTs-related traits were mainly significantly 319 enriched Adipose_Visceral_(Omentum), in Cells EBV-320 transformed_lymphocytes, Lung, Small_Intestine_Terminal_Ileum and Whole_Blood 321 tissues (FDR < 0.05) (Supplementary Fig. 4, Supplementary Table 15A). In CVDs, 322 AF showed significant enrichment in heart-related tissues (Heart_Atrial_Appendage 323 and Heart_Left_Ventricle), while CAD showed considerable enrichment in 324 artery-related tissues (Artery_Aorta, Artery_Coronary, and Artery_Tibial). Subsequent 325 LDSC-SEG chromatin analysis showed that BCTs were mostly significantly enriched in primary cells from peripheral blood (Supplementary Table 15B). In CVDs, AF was 326 327 mainly enriched in the fetal heart, and CAD was significantly enriched in the aorta 328 and coronary artery, confirming the multi-tissue gene expression results.

329

330 To overcome the limitation of the MAGMA approach (assigning SNPs to the nearest 331 gene without considering functional association), we employed eQTL Multi-marker Analysis of GenoMic Annotation (eMAGMA) to link tissue-specific cis-eQTL 332 333 information to genes to generate more biologically meaningful results (Supplementary 334 Table 16). From an analysis of 10 selected tissues, we identified 2,328 unique 335 pleiotropic genes achieving Bonferroni-corrected significance, each highly enriched 336 in at least one specific tissue. Notably, 1,875 of these genes (80.5%) were present in 337 two or more trait pairs. Among them, genes such as ABO (n=125), TMEM116 (n=99), 338 ALDH2 (n=95), and MAPKAPK5 (n=87) appeared in over half of the trait pairings, 339 each demonstrating specific tissue enrichments. In particular, the ABO gene is 340 predominantly found in liver and visceral adipose tissues; TMEM116 in the artery 341 tibial and visceral adipose tissues; ALDH2 in both artery tibial and artery aorta tissues;

342 and MAPKAPK5 in adipose subcutaneous and visceral adipose tissues. Notably, the 343 ABO gene affects the serum levels of von Willebrand factor (vWF) and soluble E-selectin³¹, which are involved in thrombosis and endothelial dysfunction, 344 respectively, and are critical for the development of cerebrovascular injury and 345 atherosclerosis^{31,32,33,34}. We further used the single-trait GWAS results to conduct 346 transcriptome-wide association study (TWAS) to identify tissue-specific pleiotropic 347 348 genes for complex traits and found 5,609 novel genes for BCTs and 20 novel genes 349 for CVDs (Supplementary Table 17). Notably, genes such as ABO and ALDH2 were 350 identified in more than half of the trait pairs, and both eQTL-based strategies 351 highlighted that ALDH2 in the 12q24.12 region was associated with a common 352 molecular mechanism for BCTs and CVDs, which may mediate CVDs 353 pathophysiology by affecting the metabolism of reactive aldehydes under oxidative 354 stress. However, the exact role of ALDH2 in the blood phenotype remains to be 355 elucidated. In addition, we further validated 81.7% of the genes identified by 356 eMAGMA using eQTL mapping using FUMA (Supplementary Table 10).

357

358 In our study, MAGMA and eMAGMA analyses identified 5,063 pleiotropic genes, of 359 which 936 (313 unique) exhibited strong evidence of colocalization and were 360 included in subsequent analyses (Supplementary Table 8 and Supplementary Table 361 12). Notably, 194 of these genes demonstrated pleiotropic effects across two or more 362 BCT-CVD trait pairs, including significant genes such as ALDH2, PHETA1, and 363 *MAPKAPK5* (all located at 12q24.12), *CCDC92* (12q24.31), and *ZNF664* (12q24.31). 364 Interestingly, the degree of pleiotropy varied significantly among some genes across 365 different categories of trait pairs. For instance, of the 18 trait pairs associated with 366 ACAD10, 15 involved Leukocyte-CVD pairs, while the remaining 3 were 367 Erythrocyte-CVD. Similarly, CCDC92 appeared in 20 trait pairs, with 15 categorized 368 as Erythrocyte-CVD, accounting for 17.9% of the total Erythrocyte-CVD. Conversely, 369 CCDC92 featured less frequently in Leukocyte-CVD (4 pairs, representing 6.1% of 370 all such pairs) and Platelet-CVD (only 1 pair, or 4.2% of these pairings).

371

372 Therefore, considering that the association of genes with CVDs may be influenced by 373 BCT type, we categorized all BCTs-CVDs trait pairs into three groups based on BCT 374 types, including Leukocytes-CVDs, Platelets-CVDs, and Erythrocytes-CVDs, with pleiotropic gene counts of 174, 117, and 164, respectively. Among the 375 376 Leukocytes-CVDs trait pairs, ACAD10, one of the specific genes, is not associated with Leukocytes-AF. ACAD10 is critical in mitochondrial fatty acid β -oxidation, 377 378 influencing leukocyte functions such as proliferation, cytokine production, and 379 adhesion molecule production. It is also an essential energy source for cardiomyocytes, underscoring its significant role in CVD pathophysiology³⁵. Among 380 381 the Platelets-CVDs pairs, TNFSF12 (TWEAK) was notably associated with PCT and 382 AF. The interaction of *TNFSF12* with the fibroblast growth factor-inducible molecule 383 14 (Fn14) activates signaling pathways essential for vascular and cardiac remodeling, pivotal in acute and chronic CVDs³⁶. Furthermore, studies have linked serum TWEAK 384 levels to PLT, highlighting clinical relevance^{33,37}. For the Erythrocytes-CVDs pairs, 385 386 CCDC92 was the most frequently pleiotropic gene, which affects the occurrence of 387 cardiovascular events by regulating adipose tissue distribution and insulin sensitivity, highlighting its broad impact on metabolic and cardiovascular health^{38,39}. 388

389

390 Potential shared biological mechanism between BCTs and CVDs

391 We performed MAGMA gene set analysis to explore specific biological pathways or 392 cellular functions implicated in the BCTs-CVDs pair's genetic etiology. A total of 1,599 pathways were significantly enriched after Bonferroni correction ($P < 3.00 \times$ 393 10⁻⁸), including 169 Gene Ontology Biological Process (GO BP) terms, 30 KEGG 394 395 pathways, and 33 Reactome pathways (Supplementary Table 18). Since most genes 396 have obvious trait specificity and participate in different biological pathways, we still 397 divide the pathways enriched by BCTs-CVDs into three categories to observe whether 398 they have specific and reliable results. Of these, 992 were associated with the 399 Leukocytes-CVDs pairs, and more than half of these involved pathways were related 400 to the regulation of immune system processes, immune responses, and cellular

activation, affecting all leukocyte phenotypes except basophil-related parameters. In
contrast, the Platelets-CVDs pairs were enriched for only 77 pathways, mainly related
to hemostasis and platelet activation, signaling, and aggregation. VTE showed strong
correlations with all four platelet parameters in these specific pathways. For the
Erythrocytes-CVDs pairs, 530 pathways were enriched, mainly involving vascular
and circulatory system development, with AF and CAD being more highly associated
with these terms than other CVDs.

408

409 Further enrichment analysis of overlapping genes in MAGMA and eMAGMA 410 analyses using Metascape confirmed that the Leukocytes-CVDs related gene set was 411 mainly involved in the inflammatory response, the Platelets-CVDs related gene set 412 focused on platelet activation and aggregation, and the Erythrocytes-CVDs related 413 gene set was mainly engaged in the regulation of hematopoietic progenitor 414 differentiation, which is highly consistent with the results of the MAGMA gene set 415 analysis(Supplementary Table 19). These findings revealed the common molecular 416 genetic mechanisms behind the extensive multi-gene overlap between the three types 417 of BCTs and CVDs, highlighting important pathways that may become therapeutic 418 targets for treating these diseases.

419

420 Identification of pathogenic proteins and drugs in cross-sectional traits

421 To investigate the associations between plasma protein expression and disease risk, 422 we employed summary-data-based Mendelian Randomization (SMR). We sourced 423 blood cis-pQTL data from the UK Biobank Pharmaceutical Proteomics Project 424 (UKB-PPP) and the deCODE Health study. After excluding entries that failed the 425 heterogeneity in dependent instruments (HEIDI) test, underwent multiple SNP-SMR 426 sensitivity analyses, and surpassed the Bonferroni correction threshold, we identified 427 1,589 causal proteins, of which 1,534 were associated with BCTs and 55 with CVDs. 428 Among these, 49, 62, and 101 overlapping proteins were associated with leukocytes, 429 platelets, and erythrocytes, respectively, from deCODE Health and UKB-PPP studies, 430 with an additional eight proteins linked to CVDs. Remarkably, our analysis uncovered

only three pleiotropic proteins across seven distinct trait pairs, specifically SERPINE2
and TNFSF12 in Platelets-CVDs pairs and GP6 in both Platelets-CVDs and
Erythrocytes-CVDs pairs. Subsequent colocalization analysis confirmed that the GP6
gene polymorphic variant rs892090 demonstrated strong colocalization in all pertinent
trait pairs except MPV-VTE (Supplementary Table 20).

436

437 Discussion

438 We discovered significant genetic overlaps between BCTs and CVDs through 439 comprehensive pleiotropic analyses of large-scale GWAS summary statistics. 440 However, evidence for a direct causal relationship remains limited. Our studies 441 identified 571,782 pleiotropic variants and 313 unique pleiotropic genes, which show 442 varied CVD risks across different BCT subgroups, including leukocytes, platelets, and 443 erythrocytes. We further explored the distinct characteristics of these blood cell 444 phenotypes, revealing that specific pathways play key roles in their pathophysiology. 445 For platelet-CVD subgroups, platelet activation is central; for erythrocyte-CVD 446 subgroups, the regulation of hematopoietic progenitor differentiation is crucial; and 447 for leukocyte-CVD subgroups, the inflammatory response is pivotal. Additionally, our 448 research has identified GP6, TNFSF12, and SERPINE2 as potential therapeutic 449 targets for these conditions. These findings underscore the value of BCT parameters 450 as biomarkers for assessing CVD risk and provide valuable insights into the genetic 451 underpinnings of these associations.

452

453 We identified a substantial genetic overlap between BCTs and CVDs using diverse 454 analytical methodologies, including LDSC, GPA, and LAVA. Our analysis indicated 455 significant genome-wide genetic correlations for 8.6% of trait pairs, corroborating 456 previous phenotypic associations and confirming a shared genetic foundation. 457 Although genome-wide r_g (averaging shared SNP effects across the genome) may 458 obscure specific genetic associations within genomic regions, we utilized LAVA to 459 pinpoint multiple specific genomic areas. We observed local- r_{es} for all trait pairs 460 within these regions, indicating confounding effects that are not evident in

461 genome-wide estimates. For instance, despite a genome-wide r_g near zero according 462 to LDSC, both BASO_P-AF and BASO-CAD demonstrated approximately equal 463 numbers of positively and negatively correlated genetic regions. This nuance 464 underscores significant genetic correlations that broader statistical frameworks might 465 overlook. Our GPA analysis further confirmed substantial polygenic overlap among 466 all trait pairs, highlighting the complex genetic interplay between BCTs and CVDs. In 467 conclusion, our study reveals an extensive shared genetic liability between BCTs and 468 CVDs, suggesting that their relationships are more robust and intricate than 469 previously recognized.

470

471 The LHC-MR method explored the causal relationship at the level of vertical 472 pleiotropy, which can reveal part of the common genetic mechanisms between BCTs 473 and CVDs. We identified 23 putative causal relationships, especially positive ones in 474 RDW_CV-VTE, Stroke-eosinophil count (EO), and Stroke-PCT, consistent with previous studies^{20,40}. The causal link for RDW_CV-VTE may be the reduced 475 476 deformability and increased aggregation of red blood cells, elevating viscosity and 477 impeding blood flow, thereby increasing VTE risk. Conversely, our findings did not 478 confirm the previously reported associations between high neut and increased risks of AF, HF, PAD, and Stroke, as suggested by Jiao *et al*⁴¹. This discrepancy could stem 479 480 from the significant sample overlap between BCTs and CVDs GWAS samples in the 481 UK Biobank, a typical challenge in two-sample Mendelian randomization analyses. 482 Our LHC-MR approach addressed and mitigated genetic confounding due to this 483 sample overlap and clarified the exposure-outcome relationships. Additionally, we 484 report for the first time a positive association between HF and several BCTs, such as 485 MPV, MSCV, PCT, and PLT, and a negative association with HCT. However, the 486 negative relationship between AF and PLT is consistent with previous studies. 487 Specifically, a meta-analysis by Alexander *et al.* indicated a significant reduction in PLT in AF patients, potentially influenced by factors such as AF type, smoking status, 488 and geographic region⁴². We found no causal associations between the remaining trait 489 pairs, and the limited causal evidence suggests that the BCTs-CVDs trait pair 490

491 associations are less driven by causality and may be primarily mediated by horizontal

492 pleiotropy.

493

494 Although we discovered that BCTs and CVDs share a common genetic foundation, it 495 remains unclear whether the association between them occurs via horizontal or 496 vertical pleiotropy. We first investigated the horizontal pleiotropy level and identified 497 multiple pleiotropic loci associated with BCTs and CVDs, among which important 498 loci such as 9q34.2, 12q24.31, and 12q24.12 affected more than 50% of the trait pairs. 499 Recent research has underscored the pleiotropic effects of genes within the 12q24.12 region on CVDs⁴³. Notably, the gene *ALDH2*, encoding aldehyde dehydrogenase 2, is 500 associated with CAD, blood pressure regulation, and alcohol-induced cardiac 501 dysfunction⁴⁴. This enzyme is essential for metabolizing both endogenous and 502 503 exogenous aldehydes; its dysfunction leads to aldehyde accumulation, markedly 504 increasing the risk of specific CVDs. Furthermore, ALDH2 modulates 505 atherosclerosis-related risk factors such as foam cell formation and macrophage effervescence through non-enzymatic pathways⁴⁵. Another critical gene in this region, 506 507 SH2B3 (also known as lymphocyte adaptor protein or LNK), regulates cytokine signaling and cell proliferation⁴⁶. In mouse models, targeted deletion of LNK disrupts 508 509 the negative feedback regulation of various pathways, affecting hematopoiesis and enhancing thrombopoietin (TPO) signaling⁴⁷. This disruption leads to increased 510 thrombosis and atherosclerosis, thereby elevating the incidence of CVD events. 511 Consistently, studies have linked the LNK rs3184504 (T allele, R262W) variant with 512 an increased risk of CAD and thrombotic stroke⁴⁸. HyPrColoc results confirm that 513 514 rs3184504 is a common pathogenic variant across CAD, VTE, and 19 other BCTs, 515 highlighting the pleiotropic role of SH2B3. The gene MAPKAPK5, which encodes the MK5 protein—a serine/threonine kinase—also shows high expression levels in the 516 human heart⁴⁹. MK5 plays a role in endothelial cell migration and angiogenesis⁵⁰ and 517 influences erythrocytes' structure, metabolism, and ion channels⁵¹, thus affecting 518 susceptibility to atherosclerosis⁵². In conclusion, the identified pleiotropic loci 519

520 associated with BCTs and CVDs reveal a strong genetic interrelation between these

521 traits, providing deeper insights into their complex genetic associations.

522

In our study, we employed two gene mapping strategies to associate candidate SNPs 523 with genes that influence both BCTs and CVDs. Specifically, among the 524 Leukocytes-CVDs trait pairs, ALDH2, MAPKAPK5, and ACAD10, all located at 525 12q24.12, were identified as significant pleiotropic genes. ACAD10, in particular, 526 plays a crucial role in activating mitochondrial fatty acid oxidation $(FAO)^{53}$, which is 527 pivotal in developing atherosclerosis through NLRP3 inflammasome activation and 528 IL-4-induced macrophage polarization⁵⁴. Notably, the FAO inhibitor trimetazidine 529 effectively prevents foam cell formation from macrophages originating from 530 circulating monocytes in the arterial intima⁵⁵. About Platelets-CVDs trait pairs, 531 TNFSF12 (17p13.1) has emerged as key pleiotropic genes. SMR studies have 532 533 demonstrated a significant association between TNFSF12 protein levels and PCT-AF. TNFSF12, also known as TWEAK, activates the JAK2/STAT3 pathway via the Fn14 534 receptor, inducing hypertrophy in HL-1 atrial myocytes—a vital adaptive change in 535 AF development⁵⁶. This pathway also influences PLT and vascular permeability³³. 536 537 Given their potential, the drugs BIIB-023 and RO-5458640, currently indicated for lupus nephritis and rheumatoid arthritis, respectively, warrant further investigation in 538 539 clinical trials to evaluate their efficacy in treating PCT and AF. Regarding Erythrocytes-CVDs trait pairs, ZNF664 and CCDC92, both located in the 12q24.31 540 region, are critical. CCDC92, a coiled-coil domain protein, is intimately associated 541 with lipid metabolism and insulin sensitivity³⁸. Insulin resistance, influenced by 542 CCDC92, leads to coronary endothelial dysfunction and promotes vascular smooth 543 544 muscle cell proliferation via insulin-like growth factor receptors, exacerbating atherosclerosis⁵⁷. At the same time, no studies have directly linked *CCDC92* with 545 erythroid characteristics; ZNF664 and CCDC92 exhibit co-regulated expression 546 patterns and engage in nearly identical molecular pathways^{58,59}. 547

548

549 Shared genetic determinants indicate common biological pathways underlying

550 Leukocytes-CVDs trait pairs. Our pathway analysis revealed that inflammatory 551 responses are critical, with TNFSF12 playing a significant role. Specifically, 552 inflammatory reactions within the vessel wall, coupled with oxidative stress from endothelial dysfunction, are pivotal in the progression of atherosclerosis⁶⁰. For 553 example, circulating monocytes infiltrate fatty streaks and differentiate into 554 macrophages with pro-inflammatory properties⁶¹. These macrophages then recruit 555 inflammatory factors, amplifying local inflammatory responses. A notable mediator, 556 557 Irg1, exacerbates inflammation by promoting the formation of neutrophil extracellular traps (NETs) and activating the NLRP3 inflammasome in macrophages, enhancing 558 IL-1 β release⁶². In analyzing Platelets-CVDs trait pairs, we focused on key processes 559 560 such as hemostasis, platelets activation, and aggregation involving GP6. Platelets, derived from megakaryocytes, are fundamental to the pathogenesis of coronary 561 thrombosis and atherosclerosis⁶³. Peptide hormone receptors on platelets may trigger 562 thrombosis⁶⁴, while the chemokines they secrete play roles in both inflammation and 563 hemostasis⁶⁵. Additionally, oxidative stress and the production of reactive oxygen 564 565 species (ROS) activate platelets, profoundly affecting CVD pathogenesis, especially 566 in older individuals. Regarding Erythrocytes-CVDs trait pairs, pathways involved in 567 vascular development and the circulatory system are crucial, with TNFSF12 also 568 implicated. Erythrocytes primarily influence blood viscosity, impacting the friction exerted on the arterial wall, a key factor in maintaining systemic arterial pressure 569 post-birth and promoting vasoconstriction⁵. Pathologically, collisions of erythrocytes 570 with the arterial wall can lead to local retention and hemolysis of their membrane 571 lipids, which are associated with both the early and late stages of atherosclerosis^{66,67}. 572 From a classification perspective, our study elucidates how different pathways 573 574 mediate the association between BCTs and CVDs, highlighting that targeted 575 regulation of key genes could significantly reduce disease risk.

576

577 Using SMR and colocalization analysis, we identified three significantly shared 578 proteins—GP6, TNFSF12, and SERPINE2—across seven trait pairs. Both GP6 and 579 TNFSF12 are key target proteins currently under clinical investigation. GP6 encodes

580 platelets glycoprotein VI, essential for collagen-dependent activation, signal transduction, and full platelets activation, adhesion, and aggregation⁶⁸. Variants in 581 GP6, such as the common variant rs1613662, are associated with increased VTE risk 582 583 and alterations in platelets function, impacting CVDs susceptibility. Although no 584 studies have reported how GP6 participates in erythrocyte physiological processes, 585 our analysis highlights that GP6 upregulation correlates with heightened VTE risk and 586 elevations in 2 platelet parameters (MPV and PDW) and 4 erythrocyte parameters 587 (HLR_P, HLR, RET_P, and RET). This suggests that the GP6 inhibitor, glenisomab, 588 may represent a promising drug repurposing opportunity to mitigate excessive VTE 589 risk and elevated platelet and erythrocyte parameters. Restingly, common CVD 590 preventive drugs such as aspirin do not target the pathogenic proteins identified in our 591 SMR analysis. This may be due to the inability of blood-based cis-eQTL analysis to 592 capture anticoagulant factors produced by the liver. Moreover, the TNFSF12 inhibitor 593 BIIB-023 could be repurposed to reduce the risk of PCT and AF complications. 594 However, the underlying mechanisms remain under-explored, highlighting our 595 proposal as novel and underscoring the need for further research.

596

In conclusion, this is the first study to characterize the pleiotropic effects of a range of BCTs and CVDs on a large scale and provide important insights into the genetic architecture widely distributed throughout the genome and the mechanisms behind common genetic diseases. These results have successively provided new clues at the level of pleiotropic SNPs and genes, biological pathways, potential drug proteins, and causal relationships and will facilitate further laboratory investigations and clinical studies.

604

605 Limitations of the study

Our study presents several limitations. First, the GWAS datasets employed to investigate BCTs and CVDs may include cases with concurrent blood cell abnormalities and CVDs, potentially introducing bias into our analysis of genetic overlap. Second, the lack of rare variants in most GWAS datasets restricts our ability

to explore pleiotropy between rare loci associated with BCTs and CVDs, which could
deepen our understanding of the disease mechanisms. Third, while minimizing
demographic bias, our focus on European populations limits our findings'
generalizability to other ethnic groups. Finally, the new pathway signals and gene loci
identified require further validation through clinical cohort studies or animal models
to bolster the robustness and credibility of our results.

616

617 STAR★Methods

618 Key resources table

REAGENT or RESOURCE	IDENTIFIER
Deposited data	
	ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKB

Blood cell traits	htp://ttp:suilger.ue.uk/pub/project/humgen/summary_suitsites/				
Blood cell traits	B_blood_cell_traits/				
Atrial fibrillation	https://www.ebi.ac.uk/gwas/studies/GCST006414				
Coronary artery disease	https://cvd.hugeamp.org/datasets.html				
Venous thromboembolism	https://www.decode.com/summarydata/				
Heart failure	https://www.ebi.ac.uk/gwas/studies/GCST009541				
Peripheral artery disease	https://cvd.hugeamp.org/datasets.html				
Stroke	https://www.ebi.ac.uk/gwas/studies/GCST90104539				
Software and algorithms					
LDSC (v1.0.1)	https://github.com/bulik/ldsc				
MiXeR (v1.3)	https://github.com/precimed/mixer				
LAVA (v0.1.0)	https://github.com/josefin-werme/LAVA				
LHC-MR (v0.0.0.9000)	https://github.com/LizaDarrous/lhcMR				
PLACO (v0.1.1)	https://github.com/RayDebashree/PLACO				
FUMA (v1.5.4)	http://fuma.ctglab.nl/				
HyPrColoc(v1.0)	https://github.com/jrs95/hyprcoloc				
MAGMA (v.1.08)	https://ctg.cncr.nl/software/magma				
e-MAGMA	https://github.com/eskederks/eMAGMA-tutorial				
TWAS	http://gusevlab.org/projects/fusion/				
SMR (v1.31)	https://yanglab.westlake.edu.cn/software/smr/				
COLOC (v5.2.1)	https://github.com/chr1swallace/coloc				
R (v.4.1.3)	https://www.r-project.org/				

619

620 **Resource availability**

621 Lead contact

- 622 Further information and requests for resources and reagents should be directed to and
- will be fulfilled by the lead contact, Luke Kong (kongluke2005@163.com).
- 624

625 Materials availability

- 626 This study did not generate new unique reagents.
- 627

628 **Data and code availability**

629 The study used only openly available GWAS summary statistics on blood cell traits 630 and cardiovascular diseases that have originally been conducted using human data. 631 GWAS summary statistics on BCTs are available at 632 ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_trait 633 s/. GWAS summary statistics on AF, HF, and Stroke are available at the GWAS Catalog (GCST90104539, GCST009541, and GCST90104539). GWAS summary 634 635 statistics on CAD and PAD are publicly available for download at the Cardiovascular 636 Disease Knowledge Portal (CVDKP) website: https://cvd.hugeamp.org/datasets.html. 637 GWAS summary statistics on VTE are obtained from the deCODE genetics website: 638 https://www.decode.com/summarydata/. All data are publicly available and listed in 639 the key resources table. No unique datasets or code were generated for this study. Any 640 additional information required for reanalysis of the data reported in this article is 641 available from the primary contact on request. 642

643 Method details

644 Study Design

Figure 1 presents the workflow for this study

646

647 **Data selection and quality control**

648 Summary statistics for 29 BCTs were retrieved from a genome-wide association study 649 of 408,112 participants of European ancestry in the UK Biobank cohort, which included data on leukocytes, platelets, and erythrocytes¹⁶. Additionally, we integrated 650 GWAS summary data on six major CVDs for individuals of European ancestry with 651 652 sample sizes exceeding 50,000 to ensure robust statistical power. Specifically, 653 summary data for AF were derived from a large-scale meta-analysis including six 654 contributing studies: the Nord-Trøndelag Health Study (HUNT), deCODE, the 655 Michigan Genomics Initiative (MGI), DiscovEHR, UK Biobank, and the AFGen Consortium, encompassed 60,620 cases and 970,216 controls of European ancestry⁶⁹. 656 657 Summary data for CAD were derived from GWAS summary statistics from a 658 genome-wide meta-analysis by the CARDIoGRAMplusC4D Consortium and UK Biobank, including 181,522 cases and 984,168 controls of European ancestry⁷⁰. 659 660 Summary data for VTE were sourced from a genome-wide association study by Jonas Chouse et al., featuring 81,190 cases and 1,419,671 controls of European ancestry⁷¹. 661 662 Summary statistics for HF were extracted from a GWAS meta-analysis by Sonia Shah 663 et al., including data from 47,309 cases and 930,014 controls of European ancestry 664 across 26 studies from the Heart Failure Molecular Epidemiology for Therapeutic Targets (HERMES) Consortium⁷². Summary statistics for PAD were obtained from a 665 large-scale GWAS meta-analysis comprising 12,086 cases and 499,548 controls of 666 European ancestry⁷³. Summary statistics for stroke, involving 73,652 cases and 667 1,234,808 controls of European ancestry, were retrieved from the GIGASTROKE 668 consortium⁷⁴. Detailed information on these GWAS summary statistics and their 669 670 original publication sources is available in Table 1.

671

We implemented stringent quality control measures to ensure the integrity of our GWAS summary data and facilitate a valid comparison between BCTs and CVDs. These included (i) aligning the data with the hg19 genome build based on the 1000 Genomes Project v3 Europeans reference; (ii) filtering out SNPs that either lacked a reference SNP ID (rsID) or had duplicated rsIDs; (iii) excluding non-biallelic SNPs, which do not have precisely two allele forms; (iv) removing SNPs with a minor allele

- 678 frequency (MAF) below 0.01, ensuring that only commonly occurring variants are
- analyzed. Following these measures, we included only common SNPs in the analysis,
- totaling 6,923,169, available across all traits.
- 681

682 Statistical Analysis

683 Genome-wide genetic correlations between BCTs and CVDs

We used LDSC to analyze the h_{SNP}^2 and r_g between 29 BCTs and 6 major CVDs. 684 LDSC helps quantify the contributions of polygenic effects by examining the 685 relationship between linkage disequilibrium scores from GWAS summary results and 686 SNP test statistics⁷⁵. Initially, univariate LDSC was used to assess the SNP-based 687 heritability for each of the 29 BCTs and 6 CVDs, which measures the proportion of 688 689 phenotypic variance explained by common genetic variants. For this analysis, we calculated LD scores using the 1000 Genomes Phase 3 European reference⁷⁶, 690 691 excluding variants within the major histocompatibility complex (MHC) region (CHR 692 6: 25–35 Mb) due to its complex LD structure. We then conducted bivariate LDSC to 693 evaluate the genetic correlations among 174 BCTs and CVDs pairwise combinations. 694 This step calculates the proportion of SNP-based heritability shared between two 695 traits, normalized by the geometric mean of their heritability estimates, with 696 correlation values ranging from -1 to +1 to indicate the direction of genetic effects. To 697 adjust for multiple comparisons, we employed the FDR method, setting an FDR 698 threshold of <0.05 to determine statistical significance.

699

700 We employed LDSC-SEG to explore whether the SNP heritability of 29 BCTs and 6 701 major CVDs is significantly correlated with tissue-specific gene expression, thereby identifying relevant tissues⁷⁷. Utilizing multi-tissue gene expression data from the 702 Genotype-Tissue Expression (GTEx) project and additional data from the Franke 703 laboratory, we analyzed patterns across 53 tissues and 152 cell types⁷⁸. Furthermore, 704 we enhanced our validation process by incorporating chromatin-based annotations 705 706 linked to six epigenetic marks: DNase hypersensitivity, H3K27ac, H3K4me1, H3K4me3, H3K9ac, and H3K36me3. These annotations included 93 tags from the 707

Encyclopedia of DNA Elements (ENCODE) project and 396 tags from the Roadmap
Epigenomics database, which validated our analysis. To determine the statistical
significance of the coefficients for the identified tissues, we applied a FDR threshold
of 0.05.

712

713 Local genetic correlation analyses between BCTs and CVDs

714 To investigate local genetic correlations between 29 BCTs and 6 major CVDs within specific genomic regions, we utilized the LAVA. LAVA computed local- r_{gS} for 2,495 715 semi-independent genetic loci, each approximately 1 Mb in size, identified by 716 717 dividing the genome into blocks with minimal LD between them. The LD reference panel, derived from the 1000 Genomes Project Phase 3 of European ancestry⁷⁶, 718 719 excluded the MHC region (chr6:25-35 Mb). Initial univariate tests ascertained the local heritability of each trait using a stringent p-value threshold of $< 1 \times 10^{-4}$ to 720 exclude loci with insignificant genetic correlation or univariate heritability. 721 Subsequently, we performed 80,126 bivariate tests on loci and traits that exhibited 722 723 significant univariate genetic signals. To address the conservative nature of the 724 Bonferroni correction, we applied a FDR of 0.05 to identify significant associations.

725

For regions identified by LAVA with evidence of shared risk loci across multiple phenotypes, we conducted a multi-trait co-localization analysis using HyPrColoc⁷⁹. This method builds on the COLOC framework and simultaneously assesses co-localization among several traits by calculating the PP of multiple traits co-localizing due to a single causal variant. A SNP with a PP exceeding 0.7 indicates a significant co-localization signal, pointing to shared causal mechanisms within the region.

733

734 Genetic overlap analysis between BCTs and CVDs

To further explore the genetic overlap between BCTs and six major CVDs, we applied the GPA⁸⁰. This method leverages GWAS summary results, using the intersection of P-values for each phenotype as input, and fits a GPA model based on

738 the resulting P-value matrix data. GPA categorizes SNPs into four groups according 739 to their association with the traits: SNPs unrelated to any traits (π 00), related only to 740 the first trait (π 10), related only to the second trait (π 01), and associated with both 741 traits (π 11). This classification helps estimate the proportions of SNPs and elucidates the causal effects on the phenotypes. The statistical significance of the genetic overlap 742 is assessed using a Likelihood Ratio Test (LRT), which tests the fit of the four-group 743 744 model against a model of independent effects. GPA assumes P-values from null SNPs 745 follow a uniform distribution, while those from non-null SNPs follow a Beta distribution. The PAR, defined as $\pi 11/(\pi 01 + \pi 10 + \pi 11)$, represents the proportion of 746 SNPs associated with both traits relative to those associated with at least one trait⁸¹. 747 To minimize the influence of LD on our GPA estimates, we performed LD pruning 748 using PLINK⁸² with genotype data from the 1000 Genomes Project Phase 3 for 749 European ancestry, selecting relatively independent SNPs⁷⁶. We then applied the FDR 750 method to correct for multiple testing, with an FDR threshold of <0.05 to determine 751 752 statistical significance.

753

754 Mendelian randomization analysis using LHCMR

755 We employed the LHC-MR method to explore potential causal relationships between 29 BCTs and 6 major CVDs⁸³. Unlike traditional polygenic MR approaches that rely 756 only on genome-wide significant SNPs, LHC-MR exploits all genome-wide variation 757 758 for causal estimation, using structural equation models to relate genome-wide 759 associations to traits and confounders. LHC-MR enhances the ability to estimate 760 bidirectional causal effects, direct heritability, and confounding effects, as well as 761 accommodate sample overlap. Moreover, we also applied traditional bidirectional MR 762 models for sensitivity analysis, including MR Egger, weighted median, inverse variance weighted (IVW), simple mode, and weighted mode⁸⁴. Estimates from LHC-MR are 763 reported as odds ratios (ORs) with corresponding 95% confidence intervals (CIs). We 764 applied a Bonferroni correction to rigorously evaluate causal relationships between 765 trait pairs, setting a significance threshold at $P < 1.44 \times 10^{-4}$ (0.05 divided by 174 pairs, 766 then divided by 2 to account for testing in both directions). A unidirectional causal 767

- relationship was established when the P-value in one direction was below the
- threshold, while in the opposite direction, it exceeded 0.05. Conversely, a
- bidirectional relationship was confirmed when the P-values in both directions were
- 771 below 1.44×10^{-4} .
- 772

773 SNP-level Analysis

774 Pleiotropic SNPs Identified by PLACO

To assess the evidence for horizontal pleiotropy between 29 BCTs and 6 major CVDs,

we utilized the PLACO. PLACO is a sophisticated statistical method designed to 776 777 detect pleiotropic associations of each variant by evaluating the hypothesis that a SNP is associated with neither or just one of the traits⁸⁵. This hypothesis is subdivided into 778 four specific scenarios: (1) H00, indicating no association with either trait; (2) H10, 779 780 suggesting an association exclusively with the first trait; (3) H01, indicating an 781 association solely with the second trait; and (4) H11, representing a pleiotropic 782 association with both traits. The test statistic is calculated as the product of the Z 783 statistics for the SNPs for each trait, which is assumed to follow a mixture distribution. To ensure accuracy, SNPs with squared Z statistics (Z^2) greater than 100 are excluded 784 from analysis. SNPs are declared significantly pleiotropic at the genome-wide level if 785 their *P*-values are less than 5×10^{-8} . 786

787

788 Genomic loci definition and functional analysis

We employed the FUMA platform⁸⁶ to identify and functionally annotate independent

790 genomic loci and pleiotropic SNPs identified through PLACO. FUMA processes

791 GWAS summary statistics to annotate and prioritize SNPs and genes, enhancing data

⁷⁹² interpretation through interactive visualizations⁷⁶. Using European population data

- from the 1000 Genomes Phase 3 as a reference, we identified independently
- significant SNPs ($P < 5 \times 10^{-8}$, $r^2 < 0.6$) from GWAS results. LeadSNPs were then
- defined from these SNPs based on mutual independence ($r^2 < 0.1$), and genomic risk
- sites were determined where SNPs were in LD ($r^2 > 0.6$). LD blocks within lead SNPs,
- separated by less than 500 kb, were combined into single sites, with the top lead SNP

798 determined by the lowest P value in each site. We then evaluated the directional 799 effects of these top SNPs by comparing Z-scores, considering them novel if 800 inconsistent with any previously reported loci for BCTs or CVDs in original GWAS. For functional and pathogenic prediction of variants, we utilized ANNOVAR, 801 applying metrics like the CADD score to predict the deleteriousness of variants based 802 803 on 67 functional annotations. SNPs with a CADD score over 12.37 were considered harmful⁸⁷. The regulatory potential of SNPs was assessed using RegulomeDB scores, 804 ranging from 1a (strong evidence of regulatory function) to 7, with lower scores 805 indicating higher activity⁸⁸. Chromatin states, predicted by ChromHMM using five 806 807 chromatin markers across 127 epigenomes, helped highlight the regulatory landscape of genomic regions⁸⁹. Lastly, SNP-gene associations were analyzed through positional 808 809 mapping within a 10 kb window of genes and eQTL mapping from GTEx v8 data to identify significant cis-SNP gene pairs within 1 Mb relevant to the studied traits. 810

811

812 **Bayesian colocalization analysis**

813 Bayesian colocalization analysis used the 'coloc' R package on pleiotropic loci annotated by FUMA to identify shared causal variants within each locus⁹⁰. This 814 815 analysis assesses whether specific loci contain a causal variation that influences two traits simultaneously. We tested five hypotheses using COLOC to evaluate different 816 scenarios of genetic influence at these loci⁹¹: PPO: no association with either trait; PP1: 817 a causal variant affects only the first trait; PP2: a causal variant affects only the 818 819 second trait; PP3: different causal variants affect each trait.; PP4: a common causal 820 variant affects both traits. Loci with a posterior probability for hypothesis four (PP.H4) 821 greater than 0.7 were deemed to exhibit significant colocalization. Within these loci, 822 the SNP showing the highest PP.H4 was identified as the putative causal variant, 823 suggesting a strong genetic link between the traits at this genomic location.

824

825 Gene-level Analysis

826 Gene-based association analysis using MAGMA

827 To identify candidate pleiotropic genes based on the pleiotropic SNPs identified by 828 PLACO and single-trait GWAS results, we employed the MAGMA. This analysis 829 utilizes multiple linear principal component regression to map SNP annotations from 830 GWAS data onto the genome, detecting gene-disease associations. MAGMA's 831 strength lies in aggregating evidence from multiple genetic variants within the same 832 gene to enhance the detection of novel genetic signals. For analytical robustness, we 833 restricted our analysis to protein-coding genes containing at least ten SNPs. Gene 834 annotations were aligned with the Genome Reference Consortium Human Build 37 835 (hg19), and the analysis incorporated the 1000 Genomes Phase 3 European LD score reference panel⁷⁶, focusing on 17,636 autosomal protein-coding genes. SNPs were 836 837 systematically assigned to genes based on their location within the gene body or 838 within a ± 10 kb window surrounding the gene. Additionally, regions within the MHC 839 (chr6:25-35 Mb) were excluded due to their complex linkage disequilibrium patterns. 840 We applied a rigorous Bonferroni correction for multiple testing across 17,636 841 protein-coding genes and 174 trait pairs, setting a stringent significance threshold for 842 the MAGMA analysis at $P < 0.05/(17,636 \times 174)$.

843

844 Investigation of the tissue-specific genes using EMAGMA and TWAS

845 To overcome limitations in identifying causal genes using traditional MAGMA, which assigns SNPs to genes within a genomic window, we implemented 846 E-MAGMA⁹² for transcriptome-wide association analysis. This enhanced approach 847 848 uses tissue-specific cis-eQTL information from the GTEx v8 to link SNPs more 849 accurately with their putative genes, thereby improving the biological interpretability 850 of gene-based association analyses in BCTs and CVDs. E-MAGMA, adhering to the 851 statistical framework of MAGMA, utilizes multiple linear principal component 852 regression models. We focused our analysis on ten GTEx v8 tissues previously 853 identified as relevant to BCTs and CVDs, including arterial, adipose, and cardiac 854 tissues. To mitigate analytical complexities, regions like the MHC (chr6:25-35 Mb) 855 were excluded, and we employed Bonferroni-corrected significance thresholds 856 tailored per tissue and trait pair, ensuring robust statistical validation.

857

Complementing our E-MAGMA analysis, we conducted TWAS⁹³ using the 858 859 Functional Summary-based Imputation (FUSION) approach. TWAS integrates gene 860 expression data with single-trait GWAS results to uncover tissue-specific genetic 861 influences. We employed various prediction models, including Best Linear Unbiased 862 Prediction (BLUP), Least Absolute Shrinkage and Selection Operator (LASSO), 863 Elastic Net, and Bayesian Sparse Linear Mixed Model (BSLMM), selecting the model 864 that provided the best prediction accuracy for each tissue. Adjustments for multiple 865 comparisons were made using the Bonferroni method across each tissue type to ensure the statistical rigor of our findings. 866

867

868 Pathway-level analysis using MAGMA and Metascape

869 We used MAGMA gene set analysis to elucidate the biological relevance of 870 pleiotropic genes identified from overlaps detected by MAGMA and subsequent pathway enrichment annotation⁹⁴. This involved a competitive gene set enrichment 871 872 analysis using MAGMA, which assesses whether genes within specific sets exhibit 873 stronger associations with the phenotype than those in other gene sets across the 874 genome. Our analysis included 9,398 gene sets from the Molecular Signatures 875 Database (MSigDB, version 2023.1), particularly focusing on the C2: Reactome 876 Pathways and C5: GO Biological Processes and various biological process sets. We applied a stringent Bonferroni correction for multiple testing, setting the threshold at 877 $P = 0.05 / (7744 + 186 + 1654) / 174 = 3.00 \times 10^{-8}$ to ensure robust statistical validity. 878

879

In addition, we used Metascape to perform pathway enrichment analysis on genes significantly identified in MAGMA and E-MAGMA analyses to elucidate the biological functions and pathways of pleiotropic genes associated with BCTs and CVDs. Metascape⁹⁵ integrates functional enrichment analysis, interaction analysis, gene annotation, and member search functions to facilitate comprehensive bioinformatics analysis of bulk genes. For pathway enrichment analysis, we used the following ontology sources: GO annotation, KEGG, and Reactome pathways. P

values below 0.01 were considered statistically significant.

888

889 Proteome-wide Mendeian Randomization analysis using SMR and

890 Colocalization analysis

To explore potential common pathogenic factors at the proteomic level between 29 891 BCTs and 6 major CVDs, we employed SMR⁹⁶. We analyzed disease GWAS data 892 and pQTL data from the deCODE Health study and the UKB-PPP. The deCODE 893 894 study measured 4,719 plasma proteins in 35,559 Icelandic individuals using the SomaScan platform, while the UKB-PPP assessed 2,940 proteins in 34,557 European 895 896 individuals using the Olink Explore platform. Instrumental variables for SMR were selected based on genome-wide significant SNPs ($P < 5 \times 10^{-8}$) located within ±1 Mb 897 of the transcription initiation sites of target genes. SMR is a novel MR method used to 898 899 determine the association between genetically determined traits, such as gene 900 expression and plasma protein levels, and outcomes of interest, such as disease 901 phenotypes. This method integrates multi-omics data to facilitate the exploration of 902 potential causal relationships between specific drug targets and diseases. To validate the observed causal associations, the HEIDI^{96} test is applied; a p-value below 0.01 903 904 indicates the presence of linkage disequilibrium and pleiotropy. For sensitivity 905 analysis, SMR employs multi-SNP-SMR for each circulating protein, setting a 906 significance threshold at p < 0.05, strengthening the main analysis's evidence. The significance level is adjusted for multiple testing using the Bonferroni method, 907 establishing the threshold at $p < 5.23 \times 10^{-7}$ (0.05 divided by 2,730 unique proteins 908 and 35 traits). We then performed Bayesian colocalization analysis to complement our 909 910 SMR findings and determine whether the same causal variants underlie the 911 associations between protein levels and disease phenotypes. A posterior probability 912 (PP.H4) greater than 0.7 indicates significant colocalization, suggesting that identical 913 genetic factors may influence protein abundance and disease outcomes concurrently.

914

915 To assess the therapeutic potential of the identified proteins, we utilized the 916 OpenTargets database, which compiles comprehensive data from 22 renowned

917 sources. These sources include genetic associations, somatic mutations, existing drugs, 918 differential expression, animal models, and insights into pathways and systems 919 biology, providing a rich foundation for identifying potential therapeutic applications. 920 The database further enhances our analysis by categorizing protein-related drugs 921 according to their clinical trial phases, as reported on the ClinicalTrials website. 922 Additionally, to ensure the reliability of our findings, we cross-referenced the 923 identified proteins against a well-curated list of druggable genes. Finally, we 924 thoroughly examined the drugs associated with these target proteins, assessing their 925 relevance and potential efficacy based on current clinical and preclinical evidence.

926

927

928 **Declaration of interests**

929 The authors declare no competing interests.

930

931 Acknowledgements

932 Not applicable.

933

934 Author contributions

L.K., F.L., B.Z. and Y.L. conceptualized and supervised this project and wrote the
manuscript. L.K. and K.Y. performed the main analyses and wrote the manuscript.
L.K., L.Z., Y.Z., M.C., and Z.H. performed the statistical analysis and assisted with
interpreting the results. Q.W. and Q.F. provided expertise in cardiovascular biology
and GWAS summary statistics. All authors provided intellectual content and approved
the final version of the manuscript.

941

References 942 943 Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, Naghavi M, Mensah GA, 1. 944 Murray CJ. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 945 2015;372(14):1333-41. doi:10.1056/NEJMoa1406656 946 Monteiro Júnior JGM, de Oliveira Cipriano Torres D, Filho DCS. Hematological Parameters as 947 Prognostic Biomarkers in Patients with Cardiovascular Diseases. Curr Cardiol Rev. 2019;15(4):274-282. 948 doi:10.2174/1573403x15666190225123544 949 Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11:117. 3 950 doi:10.1186/1741-7015-11-117 951 Libby Ρ. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-74. 4. 952 doi:10.1038/nature01323 953 Michel JB, Martin-Ventura JL. Red Blood Cells and Hemoglobin in Human Atherosclerosis and 5. 954 Related Arterial Diseases. Int J Mol Sci. 2020;21(18)doi:10.3390/ijms21186756 955 Businaro R, Tagliani A, Buttari B, Profumo E, Ippoliti F, Di Cristofano C, Capoano R, Salvati B, 6. 956 Riganò R. Cellular and molecular players in the atherosclerotic plaque progression. Ann N Y Acad Sci. 957 2012;1262:134-41. doi:10.1111/j.1749-6632.2012.06600.x 958 7. Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost. 959 2011;106(5):827-38. doi:10.1160/th11-08-0592 960 Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: A simple 8. 961 parameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2015;52(2):86-105. 962 doi:10.3109/10408363.2014.992064 963 Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease. Insights 9. 964 from the Framingham Study. Jama. 1992;267(9):1253-6. 965 10. Waterhouse DF, Cahill RA, Sheehan F, McCreery C. Prediction of calculated future cardiovascular 966 disease by monocyte count in an asymptomatic population. Vasc Health Risk Manag. 2008;4(1):177-87. 967 doi:10.2147/vhrm.2008.04.01.177 968 11. Núñez J, Miñana G, Bodí V, Núñez E, Sanchis J, Husser O, Llàcer A. Low lymphocyte count and 969 cardiovascular diseases. Curr Med Chem. 2011;18(21):3226-33. doi:10.2174/092986711796391633 970 12. Guasti L, Dentali F, Castiglioni L, Maroni L, Marino F, Squizzato A, Ageno W, Gianni M, Gaudio G, 971 Grandi AM, et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or 972 cardiac revascularisation. A systematic review on more than 34,000 subjects. Thromb Haemost. 973 2011;106(4):591-9. doi:10.1160/th11-02-0096 974 13. Haybar H, Pezeshki SMS, Saki N. Evaluation of complete blood count parameters in 975 cardiovascular diseases: An early indicator of prognosis? Exp Mol Pathol. 2019;110:104267. 976 doi:10.1016/j.yexmp.2019.104267 977 14. Williams PT. Quantile-Specific Heritability of Mean Platelet Volume, Leukocyte Count, and Other 978 Blood Cell Phenotypes. Lifestyle Genom. 2022;15(4):111-123. doi:10.1159/000527048 979 15. Lin BD, Carnero-Montoro E, Bell JT, Boomsma DI, de Geus EJ, Jansen R, Kluft C, Mangino M, 980 Penninx B, Spector TD, et al. 2SNP heritability and effects of genetic variants for 981 neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio. J Hum Genet. 2017;62(11):979-988. 982 doi:10.1038/jhg.2017.76 983 16. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, Chen MH, Raffield LM, Tardaguila M, 984 Huffman JE, et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases. Cell. 985 2020;182(5):1214-1231.e11. doi:10.1016/j.cell.2020.08.008

986 17. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, Mead D, Bouman H, Riveros-Mckay F, 987 Kostadima MA, et al. The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common 988 Complex Disease. Cell. 2016;167(5):1415-1429.e19. doi:10.1016/j.cell.2016.10.042 989 18. Zhang X, Johnson AD, Hendricks AE, Hwang SJ, Tanriverdi K, Ganesh SK, Smith NL, Peyser PA, 990 Freedman JE, O'Donnell CJ. Genetic associations with expression for genes implicated in GWAS studies 991 for atherosclerotic cardiovascular disease and blood phenotypes. Hum Mol Genet. 2014;23(3):782-95. 992 doi:10.1093/hmg/ddt461 993 19. Paaby AB, Rockman MV. The many faces of pleiotropy. Trends Genet. 2013;29(2):66-73. 994 doi:10.1016/j.tig.2012.10.010 995 20. Harshfield EL, Sims MC, Traylor M, Ouwehand WH, Markus HS. The role of haematological traits 996 in risk of ischaemic stroke and its subtypes. Brain. 2020;143(1):210-221. doi:10.1093/brain/awz362 997 21. He J, Jiang Q, Yao Y, Shen Y, Li J, Yang J, Ma R, Zhang N, Liu C. Blood Cells and Venous 998 Thromboembolism Risk: A Two-Sample Mendelian Randomization Study. Front Cardiovasc Med. 999 2022;9:919640. doi:10.3389/fcvm.2022.919640 1000 22. Yang Y, Zhou Y, Nyholt DR, Yap CX, Tannenberg RK, Wang Y, Wu Y, Zhu Z, Taylor BV, Gratten J. The 1001 shared genetic landscape of blood cell traits and risk of neurological and psychiatric disorders. Cell 1002 Genom. 2023;3(2):100249. doi:10.1016/j.xgen.2022.100249 1003 23. den Harder AM, de Jong PA, de Groot MCH, Wolterink JM, Budde RPJ, Isgum I, van Solinge WW, 1004 Ten Berg MJ, Lutgens E, Veldhuis WB, et al. Commonly available hematological biomarkers are 1005 associated with the extent of coronary calcifications. Atherosclerosis. 2018;275:166-173. 1006 doi:10.1016/j.atherosclerosis.2018.06.017

1007 24. Nikpay M, Mohammadzadeh S. Phenome-wide screening for traits causally associated with the
1008 risk of coronary artery disease. J Hum Genet. 2020;65(4):371-380. doi:10.1038/s10038-019-0716-z

25. Ellingsen TS, Lappegård J, Skjelbakken T, Brækkan SK, Hansen JB. Red cell distribution width is
 associated with incident venous thromboembolism (VTE) and case-fatality after VTE in a general
 population. Thromb Haemost. 2015;113(1):193-200. doi:10.1160/th14-04-0335

26. Bucciarelli P, Maino A, Felicetta I, Abbattista M, Passamonti SM, Artoni A, Martinelli I. Association
between red cell distribution width and risk of venous thromboembolism. Thromb Res.
2015;136(3):590-4. doi:10.1016/j.thromres.2015.07.020

1015 27. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler
1016 Thromb Vasc Biol. 2008;28(3):403-12. doi:10.1161/atvbaha.107.150474

1017 28. Hansen M, Zeddies S, Meinders M, di Summa F, van Alphen FPJ, Hoogendijk AJ, Moore KS,
1018 Halbach M, Gutiérrez L, van den Biggelaar M, et al. The RNA-Binding Protein ATXN2 is Expressed
1019 during Megakaryopoiesis and May Control Timing of Gene Expression. Int J Mol Sci.
1020 2020;21(3)doi:10.3390/ijms21030967

1021 29. Nemkov T, Stephenson D, Erickson C, Dzieciatkowska M, Key A, Moore A, Earley EJ, Page GP, 1022 Lacroix IS, Stone M, et al. Regulation of kynurenine metabolism by blood donor genetics and biology 1023 impacts red cell hemolysis in vitro in vivo. Blood. 2024;143(5):456-472. and 1024 doi:10.1182/blood.2023022052

1025 30. Ganesh SK, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, Johnson T, Castillo BA, Barnard J,

Baumert J, et al. Loci influencing blood pressure identified using a cardiovascular gene-centric array.

1027 Hum Mol Genet. 2013;22(8):1663-78. doi:10.1093/hmg/dds555

1028 31. Paterson AD, Lopes-Virella MF, Waggott D, Boright AP, Hosseini SM, Carter RE, Shen E, Mirea L, 1029 Bharaj B, Sun L, et al. Genome-wide association identifies the ABO blood group as a major locus

associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol. 2009;29(11):1958-67.

1031 doi:10.1161/atvbaha.109.192971

32. Prugger C, Luc G, Haas B, Morange PE, Ferrieres J, Amouyel P, Kee F, Ducimetiere P, Empana JP.
Multiple biomarkers for the prediction of ischemic stroke: the PRIME study. Arterioscler Thromb Vasc
Biol. 2013;33(3):659-66. doi:10.1161/atvbaha.112.300109

33. Mendez-Barbero N, Yuste-Montalvo A, Nuñez-Borque E, Jensen BM, Gutiérrez-Muñoz C,
Tome-Amat J, Garrido-Arandia M, Díaz-Perales A, Ballesteros-Martinez C, Laguna JJ, et al. The TNF-like
weak inducer of the apoptosis/fibroblast growth factor-inducible molecule 14 axis mediates histamine
and platelet-activating factor-induced subcutaneous vascular leakage and anaphylactic shock. J Allergy
Clin Immunol. 2020;145(2):583-596.e6. doi:10.1016/j.jaci.2019.09.019

1040 34. Franchini M, Lippi G. Relative Risks of Thrombosis and Bleeding in Different ABO Blood Groups.
1041 Semin Thromb Hemost. 2016;42(2):112-7. doi:10.1055/s-0035-1564832

1042 35. Lee JY, Lee BS, Shin DJ, Woo Park K, Shin YA, Joong Kim K, Heo L, Young Lee J, Kyoung Kim Y, Jin
1043 Kim Y, et al. A genome-wide association study of a coronary artery disease risk variant. J Hum Genet.
1044 2013;58(3):120-6. doi:10.1038/jhg.2012.124

1045 36. Méndez-Barbero N, Gutiérrez-Muñoz C, Blázquez-Serra R, Martín-Ventura JL, Blanco-Colio LM. 1046 Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 1047 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges. Cells. 1048 2020;9(2)doi:10.3390/cells9020405

37. Nagai M, Hirayama K, Ebihara I, Higuchi T, Imaizumi M, Maruyama H, Miyamoto Y, Kakita T,
Ogawa Y, Fujita S, et al. Serum TNF-related and weak inducer of apoptosis levels in septic shock
patients. Ther Apher Dial. 2011;15(4):342-8. doi:10.1111/j.1744-9987.2011.00966.x

38. Chasman DI, Paré G, Mora S, Hopewell JC, Peloso G, Clarke R, Cupples LA, Hamsten A, Kathiresan
S, Mälarstig A, et al. Forty-three loci associated with plasma lipoprotein size, concentration, and
cholesterol content in genome-wide analysis. PLoS Genet. 2009;5(11):e1000730.
doi:10.1371/journal.pgen.1000730

39. Ren L, Du W, Song D, Lu H, Hamblin MH, Wang C, Du C, Fan GC, Becker RC, Fan Y. Genetic ablation
of diabetes-associated gene Ccdc92 reduces obesity and insulin resistance in mice. iScience.
2023;26(1):105769. doi:10.1016/j.isci.2022.105769

40. Ellingsen TS, Lappegård J, Ueland T, Aukrust P, Brækkan SK, Hansen JB. Plasma hepcidin is
associated with future risk of venous thromboembolism. Blood Adv. 2018;2(11):1191-1197.
doi:10.1182/bloodadvances.2018018465

1062 41. Luo J, Thomassen JQ, Nordestgaard BG, Tybjærg-Hansen A, Frikke-Schmidt R. Neutrophil counts
1063 and cardiovascular disease. Eur Heart J. 2023;44(47):4953-4964. doi:10.1093/eurheartj/ehad649

Weymann A, Ali-Hasan-Al-Saegh S, Sabashnikov A, Popov AF, Mirhosseini SJ, Nombela-Franco L,
Testa L, Lotfaliani M, Zeriouh M, Liu T, et al. Platelets Cellular and Functional Characteristics in Patients
with Atrial Fibrillation: A Comprehensive Meta-Analysis and Systematic Review. Med Sci Monit Basic
Res. 2017;23:58-86. doi:10.12659/msmbr.902557

1068 43. Kim YK, Hwang MY, Kim YJ, Moon S, Han S, Kim BJ. Evaluation of pleiotropic effects among
1069 common genetic loci identified for cardio-metabolic traits in a Korean population. Cardiovasc Diabetol.
1070 2016;15:20. doi:10.1186/s12933-016-0337-1

1071 44. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, Tay WT, Chen CH, Zhang Y, Yamamoto K, et al.

1072 Meta-analysis of genome-wide association studies identifies common variants associated with blood

1073 pressure variation in east Asians. Nat Genet. 2011;43(6):531-8. doi:10.1038/ng.834

1074 45. Zhang J, Guo Y, Zhao X, Pang J, Pan C, Wang J, Wei S, Yu X, Zhang C, Chen Y, et al. The role of 1075 aldehyde dehydrogenase 2 in cardiovascular disease. Nat Rev Cardiol. 2023;20(7):495-509. 1076 doi:10.1038/s41569-023-00839-5 1077 46. Wang W, Tang Y, Wang Y, Tascau L, Balcerek J, Tong W, Levine RL, Welch C, Tall AR, Wang N. 1078 LNK/SH2B3 Loss of Function Promotes Atherosclerosis and Thrombosis. Circ Res. 1079 2016;119(6):e91-e103. doi:10.1161/circresaha.116.308955 1080 47. Bersenev A, Wu C, Balcerek J, Tong W. Lnk controls mouse hematopoietic stem cell self-renewal 1081 and quiescence through direct interactions with JAK2. J Clin Invest. 2008;118(8):2832-44. 1082 doi:10.1172/jci35808 1083 48. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D, 1084 Erdmann J, Goldstein BA, et al. Large-scale association analysis identifies new risk loci for coronary 1085 artery disease. Nat Genet. 2013;45(1):25-33. doi:10.1038/ng.2480 1086 49. Sahadevan P, Allen BG. MK5: A novel regulator of cardiac fibroblast function? IUBMB Life. 1087 2017;69(10):785-794. doi:10.1002/iub.1677 1088 50. Yoshizuka N, Chen RM, Xu Z, Liao R, Hong L, Hu WY, Yu G, Han J, Chen L, Sun P. A novel function of 1089 p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis. Mol Cell Biol. 1090 2012;32(3):606-18. doi:10.1128/mcb.06301-11 1091 51. Page GP, Kanias T, Guo YJ, Lanteri MC, Zhang X, Mast AE, Cable RG, Spencer BR, Kiss JE, Fang F, et 1092 al. Multiple-ancestry genome-wide association study identifies 27 loci associated with measures of 1093 hemolysis following blood storage. J Clin Invest. 2021;131(13)doi:10.1172/jci146077 1094 52. Erbilgin A, Civelek M, Romanoski CE, Pan C, Hagopian R, Berliner JA, Lusis AJ. Identification of CAD candidate genes in GWAS loci and their expression in vascular cells. J Lipid Res. 1095 1096 2013;54(7):1894-905. doi:10.1194/jlr.M037085 1097 53. He M, Pei Z, Mohsen AW, Watkins P, Murdoch G, Van Veldhoven PP, Ensenauer R, Vockley J. 1098 Identification and characterization of new long chain acyl-CoA dehydrogenases. Mol Genet Metab. 1099 2011;102(4):418-29. doi:10.1016/j.ymgme.2010.12.005 1100 54. Xiao S, Qi M, Zhou Q, Gong H, Wei D, Wang G, Feng Q, Wang Z, Liu Z, Zhou Y, et al. Macrophage 1101 fatty acid oxidation in atherosclerosis. Biomed Pharmacother. 2024;170:116092. 1102 doi:10.1016/j.biopha.2023.116092 1103 55. Leppänen O, Björnheden T, Evaldsson M, Borén J, Wiklund O, Levin M. ATP depletion in 1104 macrophages in the core of advanced rabbit atherosclerotic plaques in vivo. Atherosclerosis. 1105 2006;188(2):323-30. doi:10.1016/j.atherosclerosis.2005.11.017 1106 56. Hao L, Ren M, Rong B, Xie F, Lin MJ, Zhao YC, Yue X, Han WQ, Zhong JQ. TWEAK/Fn14 mediates 1107 atrial-derived HL-1 myocytes hypertrophy via JAK2/STAT3 signalling pathway. J Cell Mol Med. 1108 2018;22(9):4344-4353. doi:10.1111/jcmm.13724 1109 57. Inoue T, Matsunaga R, Sakai Y, Yaguchi I, Takayanagi K, Morooka S. Insulin resistance affects 1110 endothelium-dependent acetylcholine-induced coronary artery response. Eur Heart J. 1111 2000;21(11):895-900. doi:10.1053/euhj.1999.1872 1112 58. Neville MJ, Wittemans LBL, Pinnick KE, Todorčević M, Kaksonen R, Pietiläinen KH, Luan J, Scott RA, 1113 Wareham NJ, Langenberg C, et al. Regional fat depot masses are influenced by protein-coding gene 1114 variants. PLoS One. 2019;14(5):e0217644. doi:10.1371/journal.pone.0217644 1115 59. Kraja AT, Chasman DI, North KE, Reiner AP, Yanek LR, Kilpeläinen TO, Smith JA, Dehghan A, Dupuis 1116 J, Johnson AD, et al. Pleiotropic genes for metabolic syndrome and inflammation. Mol Genet Metab. 1117 2014;112(4):317-38. doi:10.1016/j.ymgme.2014.04.007

1118 60. Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X, Luo S, Li Z, Liu P, Han J, et al. Endothelial 1119 Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to 1120 Pharmacotherapies. Pharmacol Rev. 2021;73(3):924-967. doi:10.1124/pharmrev.120.000096 1121 61. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol. 1122 2010;7(2):77-86. doi:10.1038/nrcardio.2009.228 1123 62. Cyr Y, Bozal FK, Barcia Durán JG, Newman AAC, Amadori L, Smyrnis P, Gourvest M, Das D, Gildea 1124 M, Kaur R, et al. The IRG1-itaconate axis protects from cholesterol-induced inflammation and 1125 atherosclerosis. Proc Natl Acad Sci U S A. 2024;121(15):e2400675121. doi:10.1073/pnas.2400675121 1126 63. Fuentes F, Palomo I, Fuentes E. Platelet oxidative stress as a novel target of cardiovascular risk in 1127 frail older people. Vascul Pharmacol. 2017;93-95:14-19. doi:10.1016/j.vph.2017.07.003 1128 64. Montenont E, Echagarruga C, Allen N, Araldi E, Suarez Y, Berger JS. Platelet WDR1 suppresses 1129 platelet activity and is associated with cardiovascular disease. Blood. 2016;128(16):2033-2042. 1130 doi:10.1182/blood-2016-03-703157 1131 65. Gleissner CA. Platelet-derived chemokines in atherogenesis: what's new? Curr Vasc Pharmacol. 1132 2012;10(5):563-9. doi:10.2174/157016112801784521 1133 66. Zahid M, Mangin P, Loyau S, Hechler B, Billiald P, Gachet C, Jandrot-Perrus M. The future of 1134 glycoprotein VI as an antithrombotic target. J Thromb Haemost. 2012;10(12):2418-27.1135 doi:10.1111/jth.12009 1136 67. Jeney V, Balla G, Balla J. Red blood cell, hemoglobin and heme in the progression of 1137 atherosclerosis. Front Physiol. 2014;5:379. doi:10.3389/fphys.2014.00379 1138 68. Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost. 2001;86(1):189-97. 1139 69. Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, Herron TJ, McCarthy S, 1140 Schmidt EM, Sveinbjornsson G, et al. Biobank-driven genomic discovery yields new insight into atrial 1141 fibrillation biology. Nat Genet. 2018;50(9):1234-1239. doi:10.1038/s41588-018-0171-3 1142 70. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M, Hindy G, Zhou W, 1143 et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease 1144 in over a million participants. Nat Genet. 2022;54(12):1803-1815. doi:10.1038/s41588-022-01233-6 1145 71. Ghouse J, Tragante V, Ahlberg G, Rand SA, Jespersen JB, Leinøe EB, Vissing CR, Trudsø L, 1146 Jonsdottir I, Banasik K, et al. Genome-wide meta-analysis identifies 93 risk loci and enables risk 1147 prediction equivalent to monogenic forms of venous thromboembolism. Nat Genet. 1148 2023;55(3):399-409. doi:10.1038/s41588-022-01286-7 1149 72. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Hedman Å K, Wilk JB, Morley MP, 1150 Chaffin MD, et al. Genome-wide association and Mendelian randomisation analysis provide insights 1151 into the pathogenesis of heart failure. Nat Commun. 2020;11(1):163. 1152 doi:10.1038/s41467-019-13690-5 1153 73. van Zuydam NR, Stiby A, Abdalla M, Austin E, Dahlström EH, McLachlan S, Vlachopoulou E, 1154 Ahlqvist E, Di Liao C, Sandholm N, et al. Genome-Wide Association Study of Peripheral Artery Disease. 1155 Circ Genom Precis Med. 2021;14(5):e002862. doi:10.1161/circgen.119.002862 1156 74. Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, Kamanu FK, Koido M, Le Grand Q, 1157 Shi M, et al. Stroke genetics informs drug discovery and risk prediction across ancestries. Nature. 1158 2022;611(7934):115-123. doi:10.1038/s41586-022-05165-3 1159 75. Tobin MD, Minelli C, Burton PR, Thompson JR. Commentary: development of Mendelian 1160 randomization: from hypothesis test to 'Mendelian deconfounding'. Int J Epidemiol. 2004;33(1):26-9. 1161 doi:10.1093/ije/dyh016

1162 76. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, 1163 McVean GA, Abecasis GR. A global reference for human genetic variation. Nature. 1164 2015;526(7571):68-74. doi:10.1038/nature15393

1165 77. Finucane HK, Reshef YA, Anttila V, Slowikowski K, Gusev A, Byrnes A, Gazal S, Loh PR, Lareau C,

1166 Shoresh N, et al. Heritability enrichment of specifically expressed genes identifies disease-relevant 1167 tissues and cell types. Nat Genet. 2018;50(4):621-629. doi:10.1038/s41588-018-0081-4

1168 78. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene 1169 regulation in humans. Science. 2015;348(6235):648-60. doi:10.1126/science.1262110

1170 79. Foley CN, Staley JR, Breen PG, Sun BB, Kirk PDW, Burgess S, Howson JMM. A fast and efficient

1171 colocalization algorithm for identifying shared genetic risk factors across multiple traits. Nat Commun. 1172 2021;12(1):764. doi:10.1038/s41467-020-20885-8

1173 80. Duncan LE, Shen H, Ballon JS, Hardy KV, Noordsy DL, Levinson DF. Genetic Correlation Profile of 1174 Schizophrenia Mirrors Epidemiological Results and Suggests Link Between Polygenic and Rare Variant 1175 (22q11.2) Cases of Schizophrenia. Schizophr Bull. 2018;44(6):1350-1361. doi:10.1093/schbul/sbx174

1176 81. Chung D, Yang C, Li C, Gelernter J, Zhao H. GPA: a statistical approach to prioritizing GWAS results 1177 integrating pleiotropy and annotation. PLoS Genet. 2014;10(11):e1004787. bv 1178

1179 82. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI,

doi:10.1371/journal.pgen.1004787

1180 Daly MJ, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. 1181 Am J Hum Genet. 2007;81(3):559-75. doi:10.1086/519795

1182 83. Darrous L, Mounier N, Kutalik Z. Simultaneous estimation of bi-directional causal effects and 1183 heritable confounding from GWAS summary statistics. Nat Commun. 2021;12(1):7274. 1184 doi:10.1038/s41467-021-26970-w

1185 84. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity Analyses for Robust Causal 1186 Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. Epidemiology. 1187 2017;28(1):30-42. doi:10.1097/ede.000000000000559

1188 85. Ray D, Chatterjee N. A powerful method for pleiotropic analysis under composite null hypothesis 1189 identifies novel shared loci between Type 2 Diabetes and Prostate Cancer. PLoS Genet. 1190 2020;16(12):e1009218. doi:10.1371/journal.pgen.1009218

1191 86. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of 1192 genetic associations with FUMA. Nat Commun. 2017;8(1):1826. doi:10.1038/s41467-017-01261-5

1193 87. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for 1194 estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310-5. 1195 doi:10.1038/ng.2892

1196 88. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, Karczewski KJ, Park J, Hitz BC, 1197 Weng S, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome 1198 Res. 2012;22(9):1790-7. doi:10.1101/gr.137323.112

1199 89. Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, 1200 Wang J, Ziller MJ, et al. Integrative analysis of 111 reference human epigenomes. Nature. 1201 2015;518(7539):317-30. doi:10.1038/nature14248

1202 90. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, Plagnol V. Bayesian 1203 test for colocalisation between pairs of genetic association studies using summary statistics. PLoS 1204 Genet. 2014;10(5):e1004383. doi:10.1371/journal.pgen.1004383

1205 91. Wallace C. Eliciting priors and relaxing the single causal variant assumption in colocalisation

- 1206 analyses. PLoS Genet. 2020;16(4):e1008720. doi:10.1371/journal.pgen.1008720
- 1207 92. Gerring ZF, Mina-Vargas A, Gamazon ER, Derks EM. E-MAGMA: an eQTL-informed method to
- 1208 identify risk genes using genome-wide association study summary statistics. Bioinformatics.
- 1209 2021;37(16):2245-2249. doi:10.1093/bioinformatics/btab115
- 1210 93. Zhu H, Zhou X. Transcriptome-wide association studies: a view from Mendelian randomization.
- 1211 Quant Biol. 2021;9(2):107-121. doi:10.1007/s40484-020-0207-4
- 1212 94. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS
- 1213 data. PLoS Comput Biol. 2015;11(4):e1004219. doi:10.1371/journal.pcbi.1004219
- 1214 95. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK.
- 1215 Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat 1216 Commun. 2019;10(1):1523. doi:10.1038/s41467-019-09234-6
- 1217 96. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, Montgomery GW, Goddard ME, Wray NR,
- 1218 Visscher PM, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait
- 1219 gene targets. Nat Genet. 2016;48(5):481-7. doi:10.1038/ng.3538

1220

Trait	Abbreviations	PubMed ID	Data source	Ν	N case	N control	Reference genome	Original no. of SNPs
Basophil count	BASO	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su mmary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,265,204
Basophil percentage of leukocytes	BASO_P	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su mmary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,265,870
Eosinophil count	EO	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su mmary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,265,919
Eosinophil percentage of leukocytes	EO_P	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su mmary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,266,115
Lymphocyte count	LYMPH	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su mmary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,266,573
Lymphocyte percentage of leukocytes	LYMPH_P	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su mmary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,266,258
Monocyte count	MONO	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su mmary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,263,103
Monocyte percentage of leukocytes	MONO_P	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su mmary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,263,840
Neutrophil count	NEUT	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su mmary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,265,469
Neutrophil percentage of leukocytes	NEUT_P	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su mmary_statistics/UKBB_blood_cell_traits/	408,112	NA	NA	GRCh37 (hg19)	41,266,508
leukocyte count	WBC	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408,112	NA	NA	GRCh37	41,264,179

			mmary_statistics/UKBB_blood_cell_traits/				(hg19)	
Maan platalat voluma	MPV	22888404	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408,112	NA	NA	GRCh37	41,253,304
wean platelet volume		52888494	mmary_statistics/UKBB_blood_cell_traits/				(hg19)	
Plateletorit	РСТ	32888/19/	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408 112	NΔ	NΔ	GRCh37	41 253 096
Thateleternt	101	52000474	mmary_statistics/UKBB_blood_cell_traits/	400,112	nn.	11A	(hg19)	41,235,070
Platelet component	PDW	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408 112	NΔ	NΔ	GRCh37	41 254 093
distribution width	100	52000474	mmary_statistics/UKBB_blood_cell_traits/	400,112	142 1	1 12 1	(hg19)	41,254,075
Platelet count	PLT	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408 112	NA	NA	GRCh37	41,253,708
T latelet could	1.21	32000171	mmary_statistics/UKBB_blood_cell_traits/	400,112	1 12 1		(hg19)	
Hematocrit	нст	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408 112	NA	NA	GRCh37	41 262 764
minutoent	ner	32000171	mmary_statistics/UKBB_blood_cell_traits/	100,112	1 11 1	1 11 1	(hg19)	11,202,701
Hemoglobin	HGB	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408.112	NA	NA	GRCh37	41.261.840
measurement	HOD	32000171	mmary_statistics/UKBB_blood_cell_traits/				(hg19)	, - , 5 . 6
High light scatter	HLR	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408.112	NA	NA	GRCh37	41.252.382
reticulocyte count			mmary_statistics/UKBB_blood_cell_traits/	,			(hg19)	, - ,
High light scatter			ftp://ftp.sanger.ac.uk/pub/project/humgen/su				GRCh37	
percentage of red	HLR_P	32888494	mmary statistics/UKBB blood cell traits/	408,112	NA	NA	(hg19)	41,251,884
cells								
Immature fraction of	IRF	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408,112	NA	NA	GRCh37	41,249,976
reticulocytes			mmary_statistics/UKBB_blood_cell_traits/				(hg19)	
Mean corpuscular	MCH	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408,112	NA	NA	GRCh37	41,254,732
hemoglobin			mmary_statistics/UKBB_blood_cell_traits/				(hg19)	
Mean corpuscular	ular		ftp://ftp.sanger.ac.uk/pub/project/humgen/su	100 110		274	GRCh37	41.060.000
hemoglobin	MCHC	32888494	mmary_statistics/UKBB_blood_cell_traits/	408,112	INA	INA	(hg19)	41,262,882
concentration	MOU	22000404		400 110	NT A	NT A		41 055 055
Mean corpuscular	MCV	32888494	ttp://ttp.sanger.ac.uk/pub/project/humgen/su	408,112	NA	NA	GRCh3/	41,255,855

volume			mmary_statistics/UKBB_blood_cell_traits/				(hg19)	
Mean reticulocyte	MRV	32888494	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408.112	NA	NA	GRCh37	41.250.423
volume		52000171	mmary_statistics/UKBB_blood_cell_traits/	100,112	1.1.1	1111	(hg19)	.1,200,120
Mean spheric	MSCV	37888/10/	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408 112	NΔ	NΔ	GRCh37	41 251 154
corpuscular volume	NIDE V	52000474	mmary_statistics/UKBB_blood_cell_traits/	400,112	1474	1421	(hg19)	41,231,134
Erythroauto count	DDC	22888404	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	408 112	NA	ΝA	GRCh37	41 262 112
Eryunocyte count	KDC	32000494	mmary_statistics/UKBB_blood_cell_traits/	408,112	INA	INA	(hg19)	41,263,113
Red cell distribution	DDW CV	22000/01	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	409 112	NIA	NA	GRCh37	11 750 601
width	KDW_CV	32000494	mmary_statistics/UKBB_blood_cell_traits/	406,112	INA	INA	(hg19)	41,238,084
Deticulosyte count	DET	22000/01	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	409 112	NIA	NA	GRCh37	41 240 680
Reficultocyte coulit	KE1	32888494	mmary_statistics/UKBB_blood_cell_traits/	406,112	NA	INA	(hg19)	41,247,000
Reticulocyte fraction	DET D	22000/04	ftp://ftp.sanger.ac.uk/pub/project/humgen/su	409 112	NIA	NA	GRCh37	41 240 627
of red cells	KL1_F	32000494	mmary_statistics/UKBB_blood_cell_traits/	406,112	INA	INA	(hg19)	41,249,037
Atrial fibrillation	٨F	30061737	https://www.ebi.ac.uk/gwas/studies/GCST00	1 030 836	60.620	070 216	GRCh37	34 740 186
Athar normation	AI	50001757	6414	1,050,850	00,020	970,210	(hg19)	54,740,180
Coronary artery	CAD	26474045	https://avd.hugaamp.org/datasats.html	1 165 600	181 500	08/ 168	GRCh37	20.072.070
disease	CAD	30474043	https://evu.hugeanip.org/datasets.html	1,105,090	101,522	904,100	(hg19)	20,073,070
Venous	VTE	26658127	https://www.daaada.com/summarudata/	1 500 861	81 100	1 410 671	GRCh37	0 617 042
thromboembolism	VIL	50058457	https://www.decode.com/summarydata/	1,500,801	81,190	1,419,071	(hg19)	9,017,942
Ugart failurg	ПΕ	21010/18	https://www.ebi.ac.uk/gwas/studies/GCST00	077 222	47 200	020.014	GRCh37	9 291 262
	111,	31919410	9541	911,323	47,309	930,014	(hg19)	0,201,202
Peripheral artery	PAD	24601042	https://aud.hugaanne.aug/dataaata.html	511 624	12.086	400 549	GRCh37	10 250 121
disease	IAD	54001942	https://evu.hugeanip.org/datasets.htm	511,054	12,000	499,540	(hg19)	10,230,121
Stroke	Stroke	36180705	https://www.ebi.ac.uk/gwas/studies/GCST90	1 308 460	73 652	1 234 808	GRCh37	7 511 476
SHOKE	SUUKE	50100795	104539	1,300,400	13,052	1,234,000	(hg19)	7,311,470

1222 Table 1: Overview of 29 blood cell traits and 6 cardiovascular diseases included

1223 in this study

- 1224 Note: Overview of 29 blood cell traits and 6 cardiovascular diseases, abbreviations as
- 1225 used throughout the manuscript, associated PubMed ID, Data source and Year of
- 1226 publication, the sample size, population and reference genome on which summary
- 1227 statistics are based, and the number of SNPs included in the original summary
- 1228 statistics, before we applied filtering.



1230







Genome-wide genetic associations between BCTs and CVDs. Orange or green 1234 borders highlight significant genetic correlations (with estimates provided) if they 1235 1236 were FDR significant (FDR < 0.05) or nominally significant (p < 0.05), respectively.

Figure2 b The reverse MR analysis а The forward MR analysis baso_p-AF baso_p-CAD eo-Stroke lymph_p-VTE mono_p-Stroke neut_p-CAD wbc-AF wbc-CAD wbc-PAD mpv-HF pct-CAD pct-HF pct-Stroke pdw-VTE plt-AF plt-HF hct-AF hct-HF hgb-Stroke irf-CAD mch-CAD mscv-AF mscv-HF rdw_cv-VTE 1.1 0.8 0.9 1.0 2 3 4 Causal effect (OR) Causal effect (OR)



1237



Figure 2: Forest plot of the bidirectional causal relationship between BCTs and 1239 1240 **CVDs**

LHC-MR analysis was used to detect (a) forward (BCTs \rightarrow CVDs) and (b) reverse 1241

(CVDs \rightarrow BCTs) causal effects. Estimates and 95% confidence intervals are shown as 1242

1243 dots and error bars, respectively.

1244

1245

Figure3



1246 Figure 3: Overall landscape of the pleiotropic associations across three types of

1247 BCTs and six major CVDs

The three circular dendrograms included three BCTs (central points, including [a] 1248 leukocytes, [b] platelets, and [c] erythrocytes) and six CVDs (first circle), resulting in 1249 1250 66, 24, and 84 trait pairs (second circle). A total of 156, 81, and 192 pleiotropic loci 1251 were identified in 43, 13, and 58 trait pairs for (a) leukocyte-CVDs, (b) platelet-CVDs, 1252 and (c) erythrocyte-CVDs, respectively (third circle). Significant pleiotropic genes 1253 were further identified by MAGMA and EMAGMA, and a total of 936 pleiotropic 1254 genes co-localized for paired traits. For trait pairs with more than three pleiotropic 1255 genes, we only displayed the top three pleiotropic genes according to the priority of 1256 candidate pleiotropic genes (fourth circle).

1257

Figure1



Figure2



Figure3



